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YOUMING GUO. Protective Role of Kallistatin in Vascular Injury, 
Senescence and Aging (Under the direction of JULIE CHAO) 
 
Kallistatin, a plasma protein, consists of two essential structural elements, an 
active site and a heparin-binding domain. Kallistatin exerts pleiotropic effects on 
angiogenesis, inflammation, fibrosis and tumor growth. This study aims to decipher the 
role and mechanism of kallistatin in vascular injury, senescence and aging. First, we 
determined the effect of kallistatin on endothelial-mesenchymal transition (EndMT), a 
process mediating vascular injury, organ fibrosis and cancer progression.  Recombinant 
human kallistatin via its heparin-binding site blocked TGF-β-induced EndMT, associated 
with downregulated microRNA (miR)-21-Akt signaling and oxidative stress in human 
endothelial cells. Kallistatin’s active site is essential for stimulating antioxidant genes, 
endothelial nitric oxide synthase (eNOS) and sirtuin 1 (SIRT1) by interacting with a 
tyrosine kinase. These findings indicate that kallistatin suppresses EndMT by inhibiting 
miR-21-Akt signaling and oxidative stress. Secondly, we determined the role and 
mechanism of kallistatin in vascular senescence and aging. Kallistatin antagonized TNF-
α-induced senescence and oxidative stress, and inhibited miR-34a, a senescence 
inducer, leading to elevated SIRT1/eNOS synthesis in human endothelial progenitor 
cells. Kallistatin administration in streptozotocin (STZ)-induced diabetic mice attenuated 
aortic senescence associated with reduced miR-34a and elevated SIRT1/eNOS levels. 
Consistently, kallistatin delayed stress-induced organismal aging in Caenorhabditis 
elegans by inhibiting miR-34 and elevating the longevity gene, sir-2.1 (SIRT1 homolog) 
synthesis. Therefore, kallistatin reduces vascular senescence and aging by inhibiting 
miR-34a-SIRT1/eNOS pathway. Thirdly, we determined the role of endogenous 
kallistatin in endothelial senescence, oxidative stress and inflammation by generating 
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two strains of kallistatin knockout mice, endothelial cell-specific and general kallistatin 
knockout mice. Kallistatin via inducing an endo-protective miRNA Let-7g antagonized 
miR-34a-SIRT1-eNOS pathway and inhibited senescence, oxidative stress and 
inflammation in human endothelial cells. Conversely, kallistatin deficiency in mouse lung 
endothelial cells aggravated H2O2-induced senescence, oxidative stress and 
inflammation associated with downregulated Let-7g and antioxidant genes and 
upregulated miR-34a synthesis, indicating that kallistatin protects against endothelial 
senescence by modulating Let-7g mediated miR-34a-SIRT1-eNOS pathway. Moreover, 
systemic depletion of kallistatin exacerbated aortic oxidative stress and renal fibrosis in 
STZ-induced diabetic mice. These studies indicate that kallistatin plays a novel role in 
protection against vascular injury, senescence and aging by regulating Let-7g, miR-34a 



















α-SMA                                              
BUN 
C. elegans                                        
CLP                                                  
DCFH-DA                                          
DHE                                                  
DOCA                                               
EndMT                                              
eNOS                                                
EPC                                                  
FoxO1                                               
HMGB-1                                            
HUVECs                                            
ICAM-1                                              
IL-6                                                    
KBP                                                   
KLF4                                                  
KS                                                      
KSendo-/-                                              
KS-/-                                                   
L-NAME                                            
LPS 
MACS 
miRNA     
MMP       
NAM     
NF-κB       
PAI-1      
PBS       
PVDF 
qRT-PCR       
ROS           
SA-β-gal     
serpin  
SIRT1            
SOCS 3       
SOD                       
STZ       
TGF-β  
TNF-α             
VCAM-1         
VE-cadherin        
VEGF        
                                                                                                                                                                        
α-smooth muscle actin 
blood urea nitrogen 
Caenorhabditis elegans  
caecal ligation and puncture 




endothelial nitric oxide synthase 
endothelial progenitor cell 
forkhead box O1 
high‐mobility group box‐1 
human umbilical vein endothelial cells 
intercellular adhesion molecule-1 
interleukin-6 
tissue kallikrein-binding protein 
kruppel like factor 4 
kallistatin 
endothelium-specific kallistatin-deficient 
general kallistatin knockout 
Nω-nitro-L-arginine methyl ester hydrochloride 
lipopolysaccharide  





plasminogen activator inhibitor‐1 
phosphate-buffered saline 
polyvinylidene difluoride 
quantitative real-time polymerase chain reaction 
reactive oxygen species 
senescence‐associated β‐galactosidase 
serine proteinase inhibitor  
sirtuin 1 
suppressor of cytokine signaling-3 
superoxide dismutase 
streptozotocin 
transforming growth factor-β 
tumor necrosis factor-α 
vascular cell adhesion molecule-1 
vascular endothelial-cadherin 

















Biochemical and Molecular Properties of Kallistatin  
 Kallistatin was first identified in human plasma as a tissue kallikrein-binding 
protein  (KBP) in 1986 (Chao et al., 1986). Tissue kallikrein is a serine proteinase which 
cleaves low molecular weight kininogen to release vasoactive kinin peptide (Bhoola et 
al., 1992). Intact kinin binds to kinin B2 receptors and induces vasodilation and a wide 
spectrum of biological effects (Regoli et al., 1990). Purified and 125I-labeled human tissue 
kallikrein and human serum rapidly forms a high molecular weight complex, which is 
resistant to SDS treatment and boiling, indicating a covalent linkage between tissue 
kallikrein and a serum protein (Chao et al., 1986). Molecular cloning and sequence 
analyses indicate that KBP is a novel serine proteinase inhibitor (serpin) (Zhou et al., 
1992, Chai et al., 1993).  KBP was designated as kallistatin as it inhibited tissue 
kallikrein activity (Zhou et al., 1992, Chai et al., 1993, Chai et al., 1994). Kallistatin is an 
acidic glycoprotein with a molecular mass of 58-60 kDa and isoelectric points of 4.6 to 
5.2 (Chao et al., 1990, Zhou et al., 1992). The amino acid sequence derived from human 
kallistatin cDNA shares 44-46% homology with other human serpins (Chai et al., 1993). 
Kallistatin belongs to the serpin superfamily including α1-antitrypsin, α1-
antichymotrypsin, protein C inhibitor, plasminogen activator inhibitor, and heparin 
cofactor (Rosenberg & Damus, 1973, Baker et al., 1980, Chao et al., 1990, Ehrlich et al., 
1991). Human kallistatin gene is located on chromosome 14q31-32.1 within a serpin 
gene cluster (Billingsley et al., 1993, Chai et al., 1994). The kallistatin gene has a typical 
five exon-four intron gene structure. The full-length human kallistatin cDNA encodes 427 
amino acid residues (Chai et al., 1993, Chai et al., 1994).  
 
The three-dimensional structure of human kallistatin created by molecular 
modeling showed that kallistatin consists of three β-sheets and eight α-helices, a 
property similar to other serpins (Chen et al., 2000, Chen et al., 2001). Kallistatin 
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contains two structural elements: an active site and a heparin-binding domain (Chen et 
al., 2000, 2000, Chen et al., 2001). Human kallistatin is a unique serpin as it contains a 
reactive center sequence, Phe-Phe-Ser (P2-P1-P1’), for the cleavage site of tissue 
kallikrein (Chen et al., 2000).  Moreover, heparin prevents the formation of tissue 
kallikrein-kallistatin complex and inhibitory effect of kallistatin on tissue kalllikrein’s 
enzymatic activity, leading to the identification of a major heparin-binding site in 
kallistatin (Chen et al., 2001). The basic residues, particularly Lys312-Lys313, in the 
region between the H helix and C2 sheet of kallistatin, comprise a major heparin-binding 
site (Chen et al., 2001). Kallistatin via its two structural domains regulates multiple 
signaling pathways and a wide spectrum of biological activities.  
 
Figure 1-1. Molecular model of human kallistatin according to α1-antitrypsin. Active site 
is located in the reactive center loop, heparin-binding domain is located between C2 
sheet and H helix as indicated by the arrows (Chen et al., 2000; Chen et al., 2001). 
 
Kallistatin via Its Structural Elements Regulates Biological Functions 
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Kallistatin through its two functional domains regulates different signaling 
pathways independent of tissue kallikrein. On one hand, kallistatin via its active site 
inhibits tissue kallikrein’s enzymatic activity, thus the biological function (Chen et al., 
2000). On the other hand, kallistatin via its heparin-binding site interacts with cellular 
surface heparan sulfate proteoglycans, thus antagonizing vascular endothelial growth 
factor (VEGF)-induced proliferation and migration of human endothelial cells (Miao et al., 
2003). Likewise, kallistatin’s heparin-binding site is essential for competing with tumor 
necrosis factor (TNF)-α binding to heparan-sulfate proteoglycans, and thus blocking 
TNF-α–induced nuclear factor (NF)-κB activation and inflammatory gene expression in 
endothelial cells (Yin et al., 2010). Similarly, kallistatin via the heparin-binding site 
antagonized high mobility group box-1 (HMGB1)-mediated inflammation, and EGF-
mediated caner cell proliferation and invasion (Li et al., 2014, Li P. et al., 2016). Thus, 
through the active site and heparin-binding domain, kallistatin exerts pleiotropic 
functions, including inhibition of angiogenesis, inflammation and cancer development 
(Chen et al., 2000, Miao et al., 2003, Yin et al., 2010, Li et al., 2014, Li et al., 2016).  
 
Distribution and Expression of Kallistatin  
Kallistatin is mainly synthesized in the liver, and is widely distributed in organs 
relevant to cardiovascular function (Chao & Chao, 1995). Human kallistatin transcripts 
and protein can be detected in the plasma, liver, heart, lung, kidney, prostate gland and 
aorta (Chai et al., 1993, Chao & Chao, 1995, Chao et al., 1996). Kallistatin is also 
localized in endothelial cells and smooth muscle cells of large, medium, and small blood 
vessels (Wolf et al., 1999). Circulating kallistatin levels are markedly decreased in 
animal models of hypertension, streptozotocin (STZ)-induced diabetes mellitus, 
lipopolysaccharide (LPS)-induced endotoxemia, renal injury and hepatocellular 
 
 5 
carcinoma (Chao et al., 1990, Chao et al., 1996, Chen et al., 1997, Shen et al., 2008, Zhi 
et al., 2015). Importantly, kallistatin levels are significantly lower in patients with liver 
disease, septic syndrome, diabetic retinopathy, severe pneumonia, inflammatory bowel 
disease, and colon and prostate cancer (Chao et al., 1996, Ma et al., 1996, Stadnicki et 
al., 2003, Lin et al., 2013, Chao et al., 2016). Moreover, reduced plasma kallistatin levels 
are associated with adiposity and cardiometabolic risk in apparently healthy African 
American youths (Zhu H. et al., 2013). These findings indicate that kallistatin is reduced 
under various pathological conditions, implicating the involvement of kallistatin in 
cardiovascular damage. 
 
Kallistatin Is A Vasodilator Independent of Tissue Kallikrein  
  The first pivotal finding regarding kallistatin’s function in vascular biology is 
kallistatin-mediated reduction of blood pressure. The levels of kallistatin mRNA and 
protein in tissues and serum are significantly lower in spontaneously hypertensive rats 
compared with normotensive control rats (Chao & Chao, 1988). Moreover, the 
expression of the hepatic kallistatin is markedly reduced in N-nitroarginine methyl ester 
(L-NAME)-induced arterial hypertensive rats (Chao et al., 1996). Overexpression of rat 
kallistatin in transgenic mice results in significant reduction in blood pressure compared 
with the control littermates (Chen et al., 1996). These findings indicate a potential role of 
kallistatin in blood pressure regulation. Importantly, kallistatin was identified to be a 
potent vasodilator in 1997 (Chao et al., 1997). Human kallistatin administration produced 
a rapid and transient reduction in mean arterial blood pressure in rats, and caused 
vasorelaxation in aortic rings and perfused rat kidney (Chao et al., 1997). Additionally, 
the blood pressure-lowering effect induced by kallistatin is independent of its interaction 
with tissue kallikrein, as icatibant (Hoe 140), a bradykinin B2-receptor antagonist, had no 
effect on the hypotensive effect of kallistatin but abolished kallikrein/kinin-mediated blood 
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pressure reduction (Chao et al., 1997). Moreover, the nitric oxide synthase inhibitor, L-
NAME blocked kallistatin-mediated vasodilatory effect in rats (Chao et al., 2016), 
indicating that kallistatin induces vasodilation, in part, through stimulation of NO 
production. Therefore, these findings indicate that kallistatin is a vasodilator and plays a 
role in maintaining normal blood pressure unrelated to the interaction with tissue 
kallikrein. 
 
Kallistatin Inhibits Vascular Inflammation 
 TNF-α, a potent pro-inflammatory cytokine, activates the transcription factor NF-
κB and promotes inflammatory gene expression, leading to increased oxidative stress, 
vascular inflammation and endothelial dysfunction (Lawrence, 2009). In cultured 
endothelial cells, kallistatin via the heparin-binding site inhibited TNF-α-induced NF-κB 
activation and monocyte adhesion to endothelial cells, as well as cell adhesion molecule 
and cytokine expression, including ICAM-1, VCAM-1 and MCP-1 (Shen et al., 2009, Yin 
et al., 2010). Moreover, kallistatin gene delivery attenuated mouse vascular leakage 
induced by complement factor C5a, and reduced VEGF-induced endothelial cell 
permeability (Yin et al., 2010). Kallistatin gene or protein therapy alleviated joint swelling 
and inflammation in rats with joint arthritis, inhibited renal inflammation in diabetic db/db 
mice and caecal ligation and puncture (CLP)-induced septic mice, and ameliorated lung 
injury and inflammation in LPS-challenged mice (Yin et al., 2010, Li et al., 2014, Lin et 
al., 2015, Yiu et al., 2016). Kallistatin also antagonized the pro-inflammatory mediator 
HMGB1-induced inflammatory cytokine expression through its heparin-binding site in 
endothelial cells (Li et al., 2014). Moreover, kallistatin via interaction with the 
transcription factor kruppel like factor (KLF) 4 induced eNOS expression, leading to the 
inhibition of vascular inflammation (Shen et al., 2009). eNOS promotes bioavailable NO 
production. NO plays a critical role in inhibiting inflammatory gene expression by 
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preventing NF-κB activation (Matthews et al., 1996). Overall, these findings indicate that 
kallistatin exhibits potent anti-inflammatory actions.  
 
Kallistatin Inhibits Endothelial Apoptosis  
Cell apoptosis, the programmed cell death, occurs in both physiological and 
pathological conditions in the cardiovascular system. The pathogenesis of cell apoptosis 
is commonly implicated in heart failure, myocardial infarction and other cardiovascular 
diseases (Bennett, 2002). The cardiomyocytes in cardiac tissue and endothelial cells in 
vascular wall are the typical cells afflicted by apoptosis. Kallistatin has been shown to 
attenuate cardiomyocyte apoptosis in rats at 1 day after acute myocardial ischemia-
reperfusion (I/R) injury, and reduce renal tubular necrosis in mice with I/R (Chao et al., 
2006, Zhou et al., 2015). Kallistatin-mediated anti-apoptotic actions in the kidney and 
heart suggest the potential protective role of kallistatin in vascular rarefaction. Indeed, 
kallistatin gene delivery prevented glomerular capillary loss in hypertensive rats (Shen et 
al., 2010, Gao et al., 2014). However, depletion of endogenous kallistatin augmented 
endothelial loss and aortic oxidative injury in deoxycorticosterone acetate (DOCA)-salt 
induced hypertensive rats (Liu Y. et al., 2012, Gao et al., 2014). These studies 
substantiate the role of kallistatin in vascular protection.  
 
Endothelial cells line the blood vessel and compose the inner layer of blood 
vessel wall. Kallistatin has the ability to attenuate TNF-α-induced endothelial apoptosis 
through inhibition of reactive oxygen species (ROS) and activation of Akt-eNOS 
signaling (Shen et al., 2010). Circulating endothelial progenitor cells (EPCs) are a subset 
of mononuclear cells derived from bone marrow that have regenerative capacity to 
differentiate into mature endothelial cells (Yoder, 2012). Reduced EPC number is 
associated with defective proliferation and mobility as well as accelerated apoptosis and 
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senescence (Imanishi et al., 2008). Kallistatin gene transfer increased circulating EPC 
number in hypertensive rat model, and promoted EPC migration, adhesion and tube 
formation associated with NO stimulation in vitro (Gao et al., 2014). In contrast, 
kallistatin depletion by kallistatin neutralized antibody injection decreased EPC levels 
and exacerbated vascular oxidative stress and endothelial rarefaction (Liu Y. et al., 
2012, Gao et al., 2014). Collectively, kallistatin protects against vascular injury via 
attenuating endothelial cell apoptosis and enhancing EPC mobility and function.  
 
Kallistatin Protects against Oxidative Organ Damage  
Oxidative Stress	plays a pivotal role in pathological events such as inflammation 
and organ injury. Inhibition of oxidative stress is crucial for alleviation of oxidative multi-
organ damage. Time-dependent elevation of circulating ROS levels are associated with 
reduced kallistatin levels in animal models of hypertension and renal injury (Shen et al., 
2008, Shen et al., 2010). Kallistatin’s antioxidant activity has been exhibited in multiple 
animal models, including hypertension, myocardial infarction, sepsis and diabetes (Chao 
et al., 2006, Shen et al., 2008, Shen et al., 2010, Li et al., 2015, Yiu et al., 2016). With its 
antioxidant activity, kallistatin administration reduced organ injury and improved survival 
in mice with CLP-induced polymicrobial sepsis, and alleviated LPS-induced acute lung 
injury in mice (Huang et al., 2014, Li et al., 2014, Lin et al., 2015). Kallistatin gene 
transfer displayed a renoprotective effect partially by its antioxidant action in diabetic 
db/db mice (Yiu et al., 2016). Moreover, kallistatin gene delivery attenuated organ 
damage in conjunction with decreased ROS formation and increased eNOS and NO 
levels in animal models of myocardial infarction and hypertension (Chao et al., 2006, 
Shen et al., 2008, Shen et al., 2010). Conversely, endogenous kallistatin depletion by 
neutralizing antibody injection aggravated cardiovascular and renal lesions, 
accompanied by elevated oxidative stress, inflammation and hypertrophy in hypertensive 
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rats (Liu Y. et al., 2012). NO is capable of inhibiting NADPH oxidase activity (Selemidis 
et al., 2007), thus promoting NO bioavailability should lead to the attenuation of oxidative 
stress. Kallistatin increases NO formation by activating Akt-eNOS signaling pathway 
(Shen et al., 2010, Gao et al., 2014). Moreover, kallistatin via NO formation inhibits 
NADPH oxidase activity provoked by TNF-α, H2O2 or angiotensin II in cultured renal 
cells, cardiomyocytes, myofibroblasts, EPCs and endothelial cells (Gao et al., 2008, 
Shen et al., 2008, Shen et al., 2009, Shen et al., 2010, Yin et al., 2010, Gao et al., 
2014). Taken together, these findings indicate that kallistatin through its antioxidant 
actions protects against multi-organ damage. 
 
Kallistatin Inhibits Organ Fibrosis and Tumor Growth 
        Myofibroblast accumulation, aberrant angiogenesis and vascular remodeling are 
the common features of organ fibrosis and tumor growth (Wynn, 2008). Kallistatin 
administration attenuated salt-Induced renal fibrosis and collagen expression in 
hypertensive rats, and reduced carbon tetrachloride-induced liver fibrosis in rats, 
associated with decreased oxidative parameter including malondialdehyde level and 
superoxide dismutase activity (Huang et al., 2014). Kallistatin overexpression in db/db 
diabetic mice allevated glomerulosclerosis and tubular interstitial injury and attenuated 
renal fibrosis by inhibiting TGF-β signaling (Yiu et al., 2016). TGF-β is a central regulator 
of fibrosis. In contrast, kallistatin depletion by neutralizing antibody injection worsened 
renal fibrosis by elevating fibrotic gene expression and myofibroblast number (Liu Y. et 
al., 2012). Moreover, adenovirus carrying the human kallistatin gene inhibited tumor 
growth in nude mice with human breast tumor xenografts (Miao et al., 2002). Lentivirus-
mediated kallistatin gene delivery dramatically decreased pulmonary tumor metastasis in 
association with reduced angiogenesis and inflammation in mice bearing pulmonary 
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tumor (Strait & Lakatta, 2012). Therefore, kallistatin administration displays potential 
application value for controlling fibrosis formation and tumor growth and metastasis. 
 
Potential Role of Kallistatin in Vascular Injury, Senescence and Aging  
Aging is one of the dominant risk factors for the development of cardiovascular 
disease (Lakatta, 2002). It is well known that aging is associated with a decreased 
capacity to repair and regenerate damaged blood vessels. Cellular senescence can 
acquire senescence-associated secretory phenotype (SASP) causes vascular 
rarefaction, inflammation and fibrosis (Clements et al., 2013). Endothelial-mesenchymal 
transition (EndMT) remodels vascular structure by rarefaction of endothelial cells but 
thickening of smooth muscle layers. EndMT is a critical process mediating organ fibrosis 
and tumor progression. Kallistatin has been known to inhibit organ fibrosis and tumor 
growth in animal models. It is not yet known whether kallistatin through regulating 
EndMT to inhibit organ and vascular injury. Moreover, plasma kallistatin levels are 
decreased in multiple aging-associated vascular diseases, including hypertension, 
coronary artery disease and diabetes. Plasma kallistatin levels are recently reported to 
be positively associated with leukocyte telomere length in African Americans (Zhu et al. 
2016). As leukocyte telomere length shortens with age and is a valuable biomarker for 
cellular senescence and organismal aging (Shammas, 2011), thus kallistatin may have a 
potential protective role in age-related vascular diseases. Oxidative stress is a particular 
important inducer of organ fibrosis and vascular senescence (Chen et al., 2008, 
Erusalimsky, 2009). Therefore, enhancing cellular antioxidant defense is an effective 
means to alleviate vascular injury and aging.  
 
At the molecular level, eNOS plays a crucial role in regulating vascular tone, 
proliferation and oxidative stress via NO production (Forstermann & Munzel, 2006). 
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SIRT1 as a longevity gene stimulates the expression eNOS and other antioxidant 
enzymes, such as manganese superoxide dismutase (MnSOD) and catalase, 
contributing to vascular endothelial homeostasis (Chen et al., 2010, Olmos et al., 2013, 
Xia et al., 2013). Conversely, microRNA (miR)-34a and miR-21 have emerged as 
important regulators of cellular senescence and aging (Ito et al., 2010, Zhu S. et al., 
2013). Let-7g as an endo-protective miRNA, has been shown to improve multiple 
endothelial functions by inhibiting senescence and inflammation (Liao et al., 2014). miR-
21-Akt pathway is also involved in EndMT process (Kumarswamy et al., 2012). 
Therefore, kallistatin may exert a novel function in inhibiting vascular injury, senescence 
and aging by regulating eNOS, SIRT1, miR-34a, miR-21 and Let-7g. Studying the role 
and mechanism of kallistatin in vascular injury, senescence and aging process will foster 
the development of kallistatin-based therapeutic strategies for aging-related vascular 




The object of this research project is to determine the role and mechanism of 
kallistatin in vascular injury, senescence and aging. To achieve this goal, we generated 
two strains of kallistatin knockout mice, systemic kallistatin depletion and endothelial 
cell-specific kallistatin depletion. We hypothesized that kallistatin protects against 
vascular and organ injury, senescence and aging by downregulating miR-34a and miR-
21, and upregulating Let-7g and antioxidant genes, SIRT1 and eNOS. We explored the 
role of kallistatin in regulating vascular injury and senescence using: 1) recombinant 
kallistatin protein administration, and 2) kallistatin deficiency in mouse lung endothelial 




I. To determine the role and mechanism of kallistatin in endothelial-mesenchymal 
transition. 
 
II. To determine the role and mechanism of kallistatin in vascular senescence and 
aging. 
 
III. To determine the role of endogenous kallistatin in endothelial senescence, 























Kallistatin exhibits anti-tumor and anti-fibrotic activities in animal models. 
Endothelial-mesenchymal transition (EndMT) is one of the underlying mechanisms 
contributing to fibrosis and cancer. Endothelial transdifferentiation is also activated and 
contributes to the maladaptive remodeling of vasculature, leading to rarefaction of 
endothelium and thickening of smooth muscle layers. Transforming growth factor-β 
(TGF-β) is the most common inducer of EndMT. Recombinant human kallistatin 
treatment blocked TGF-β-induced EndMT in human endothelial cells, as evidenced by 
morphological changes as well as increased endothelial marker expression of VE-
cadherin and CD31, and reduced mesenchymal marker α-SMA expression. Kallistatin 
inhibited TGF-β-mediated reactive oxygen species (ROS) formation and NADPH 
oxidase expression and activity. Kallistatin blocked TGF-β-induced miR-21-Akt survival 
pathway activation, including Akt phosphorylation, NF-κB activation, Snail1 synthesis, 
and matrix metalloproteinase 2 synthesis and activation. Kallistatin via its heparin-
binding site blocked TGF-β-induced miR-21, Snail1 expression and ROS formation. 
Conversely, kallistatin through its active site stimulated the synthesis of endothelial nitric 
oxide synthase (eNOS), sirtuin 1 (SIRT1) and forkhead box O1 (FoxO1), via interacting 
with a tyrosine kinase. These combined findings reveal that kallistatin suppresses 
EndMT by inhibiting TGF-β-induced miR-21-Akt pathway and oxidative stress and 
stimulating the expression of antioxidant genes. The study may provide new insights into 





Endothelial–mesenchymal transition (EndMT) is a critical underlying mechanism 
for organ fibrosis and tumor metastasis (Lin et al., 2012). In adults, abnormal 
differentiation of EndMT-derived fibroblast-like cells results in fibrosis in the heart, kidney 
and lung (Zeisberg et al., 2008, Hashimoto et al., 2010, Braitsch et al., 2013). Moreover, 
in later stage of vascular disease EndMT is also activated and contribute to the 
maladaptive remodeling of vasculature, leading to vascular injury including rarefaction of 
endothelium and thickening of smooth muscle layers (Lin et al., 2012, Nicolosi et al., 
2016). TGF-β signaling has been shown to be involved in controlling endothelial and 
epithelial plasticity by eliciting their transition to a mesenchymal state (Yoshimatsu & 
Watabe, 2011, van Meeteren & ten Dijke, 2012). The TGF-β-Akt-Snail axis is one of the 
important pathways in epithelial–mesenchymal transition (EMT) (Peinado et al., 2003). 
TGF-β induces Akt activation and nuclear factor-κB (NF-κB) nuclear translocation (Huber 
et al., 2004, Meadows et al., 2009), leading to elevated expression of the Snail 
transcription factor and thus reduced epithelial (E)-cadherin expression (Julien et al., 
2007). Snail also mediates downregulation of vascular endothelial (VE)-cadherin 
expression (Cheng et al., 2013). Typical morphology changes of EndMT include loss of 
cell–cell junctions, such as VE-cadherin and CD31, as well as gain of invasive and 
migratory properties characterized by mesenchymal markers, including α-smooth muscle 
actin (SMA), fibronection and N-cadherin. Additionally, aberrant expression of 
microRNAs (miRs) is implicated in EndMT-related diseases. One such miRNA, miR-21 
is markedly upregulated during fibrosis and cancer (Kumarswamy et al., 2012, Luo et al., 
2015). It has been reported that TGF-β-induced EndMT is partly regulated by miR-21-
Akt pathway, as blockade of miR-21 was found to prevent EndMT and inhibit Akt 
activation (Kumarswamy et al., 2012). Moreover, reactive oxygen species (ROS) 
production further stimulates miR-21 synthesis (Ling et al., 2012), and oxidative stress 
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contributes to cell invasion and fibrogenesis. Therefore, miR-21 and ROS are the major 
mediators of EndMT, and thus EndMT-associated vascular and organ injury. 
 
Kallistatin gene or protein delivery has been shown to improve cardiac and renal 
function, and decrease cardiac and renal fibrosis in conjunction with reduced superoxide 
formation and increased eNOS expression and NO production in animal models (Chao 
et al., 2006, Gao et al., 2008, Shen et al., 2008). Specifically, kallistatin reduced collagen 
accumulation, collagen fraction volume and TGF-β1 expression in the myocardium of 
mice with myocardial infarction (Gao et al., 2008). Kallistatin inhibited renal fibrosis and 
aortic injury in hypertensive rats (Shen et al., 2008, Shen et al., 2010). Liver fibrosis was 
also decreased upon kallistatin treatment via inhibition of oxidative stress (Huang et al., 
2014). Moreover, kallistatin has displayed inhibitory effect on tumor growth in mice with 
breast tumor xenografts (Miao et al., 2002). These findings led us to investigate the role 
and mechanism of kallistatin in modulating EndMT, the process underlying vascular 




Materials and Methods 
Cell Culture 
Human umbilical vein endothelial cells (HUVECs) were kindly provided by Dr. 
Robin Muise-Helmericks (Medical University of South Carolina). HUVECs were cultured 
in endothelial cell basal medium (EBM)-2 supplemented with EGM-2 SingleQuots 
(Lonza), and maintained in a humidified atmosphere of 5% CO2 in air at 37°C. HUVECs 
were incubated in the presence or absence of kallistatin (1 µM) for 30 min, followed by 
the addition of 10 ng/ml TGF-β1 (R&D Systems) for another 24 h (for gene analysis) or 
72 h (activity assay or protein expression). Culture media containing TGF-β1 or 
kallistatin were replaced every 24 h. In another set of experiments, cells were pretreated 
with 5 µM genistein (Sigma) for 30 min, and then further incubated with 2 µM WT-KS, 
HM-KS or AM-KS in the presence of 10 µg/ml polymyxin B sulfate (Sigma) for 30 min 
followed by stimulation with TGF-β1 for another 24 h. 
 
Purification and Characterization of Recombinant Human Kallistatins 
Recombinant human kallistatin was secreted into the serum-free medium of 
cultured human embryonic kidney cells (HEK293T). Cultured medium was concentrated 
by ammonium sulfate precipitation followed by nickel-affinity chromatography as 
described (Chen et al., 2000, Li et al., 2014). Recombinant wild-type kallistatin (WT-KS), 
heparin-binding site mutant (K312A/K313A) kallistatin (HM-KS), and active-site mutant 
(A377T) kallistatin (AM-KS) were expressed in E. coli and purified as described (Chen et 
al., 2000). The purity and identity of human kallistatin were verified by sodium dodecyl 
sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE) and western blot using a 
specific monoclonal antibody (Chao et al., 1996, Li et al., 2014). 
 
Detection of ROS Formation and NF-κB Activity Assay 
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Intracellular ROS generation was detected using the peroxide-sensitive 
fluorescent probe 2’, 7’-dichlorofluorescin diacetate (DCFH-DA; Sigma) as described 
previously (Shen et al., 2010). Phosphorylated NF-κB activities in nuclear lysates were 
determined using ELISA kit (Cell Signaling Technology) according to the manufacturer’s 
instructions. 
 
Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) 
RNA was isolated from cells using Trizol reagent (Invitrogen) per the 
manufacturer’s instructions. Total RNA was reverse-transcribed using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) for messenger RNA, or microRNA 
Reverse Transcription Kit (Applied Biosystems) for microRNA. qRT-PCR was performed 
with Taqman Gene Expression Assay (Applied Biosystems). The following human 
primers were purchased from Applied Biosystems: 18S (Hs 99999901_sl), U6 (001973), 
hsa-miR-21-3p (002438), eNOS (Hs 01574659_ml), MMP2 (Hs 00234422_ml), Snail1 
(Hs 00195591_ml), SIRT1 (Hs 01009006_ml), forkhead box O1 (FoxO1) (Hs 
01054576_ml), and NADPH oxidase 4 (Nox4) (Hs 00418356_ml). Data were analyzed 
with 2−ΔΔCt value calculation using 18S or U6 for normalization. 
 
Measurement of NADPH Oxidase Activity 
The enzymatic activity of NADPH oxidase in cell or aortic homogenates was 
assessed by lucigenin enhanced chemiluminescence (ECL) as previously described 
(Shen et al., 2010). Protein concentrations were measured by Pierce BCA protein assay 
kit (Thermo Fisher Scientific). The chemiluminescence signal was corrected for by the 





Conditioned HUVEC medium was collected and centrifuged for zymography. 
Briefly, the medium was mixed with non-reducing loading buffer and resolved at 125 V 
by 10% SDS-PAGE separating gels copolymerized with 1 mg/ml gelatin. The renaturing 
buffer (2.5% Triton X-100) was used to restore the enzyme activity. The gels were 
incubated in fresh developing buffer at 37°C for 16 h, followed by staining with 
Coomassie blue to visualize the proteolytic bands. 
 
Western Blot Analysis 
Cells were lysed in lysis buffer supplemented with a protease inhibitor cocktail 
(Thermo Fisher Scientific), and separated on a 10% polyacrylamide gel, and transferred 
on polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences). After being 
blocked for 1 h in a buffer containing 5% nonfat milk, PVDF membranes were then 
probed with primary antibodies to phosphorylated Akt (S473), total Akt, CD31, VE-
cadherin, α-SMA and α-tubulin (Cell Signaling Technology) overnight at 4°C. The 
respective horseradish peroxidase-labeled secondary antibodies were then added to the 
membrane for 1 h at room temperature. Chemiluminescence was detected by an ECL-
plus kit (GE Healthcare). 
 
Statistical Analysis 
Data are expressed as means ± SE of three independent experiments. Statistical 
significance was determined by analysis of variance with Fisher’s probability least-
squares difference test or Student t-test using GRAPHPAD PRISM software. A value of 




Kallistatin Inhibits TGF-β-Induced EndMT and Conserves the Endothelial 
Phenotype 
We first determined the effect of kallistatin on TGF-β1-mediated EndMT in 
cultured endothelial cells. Exposure of HUVECs to TGF-β1 for 3 days caused an obvious 
alteration in cellular morphology from a polygonal, cobblestone-like shape to a more 
spindle, fibroblast-like shape (Figure 2-1 A). In contrast, kallistatin treatment markedly 
suppressed the transition by conserving the endothelial phenotype. Cells undergoing 
EndMT were characterized with the expression of fibroblast marker α-SMA and 
endothelial markers VE-cadherin and CD31. Representative immunostaining showed 
that TGF-β1-induced EndMT was associated with reduced CD31 and VE-cadherin levels 
(Figure 2-1 B&C) and increased α-SMA levels (Figure 2-1 D). However, upon kallistatin 
treatment, most cells were positive for VE-cadherin and CD31, and negative for α-SMA. 
These observations were further confirmed by western blot analysis. In the presence of 
TGF-β1, VE-cadherin and CD31 protein levels were greatly reduced, and α-SMA protein 
levels were increased (Figure 2-1 E). However, kallistatin treatment reversed TGF-β1-
mediated effects. Quantitative analysis of the western blots verified our results. These 
findings demonstrate that kallistatin suppresses EndMT induced by TGF-β. 
 
Kallistatin Inhibits TGF-β-Induced ROS Formation and NADPH Oxidase 
Expression and Activity 
We next determined the effect of kallistatin on ROS formation driven by TGF-β1 
in endothelial cells. TGF-β1 significantly stimulated ROS formation compared to the 
control group, whereas kallistatin reversed TGF-β’s effect by restoring ROS production 





















Figure 2-1 A&B. Kallistatin (KS) inhibits TGF-β-induced EndMT. (A) Representative 
images of endothelial morphology under light microscope. Original magnification 200✕. 
(B) Representative immunofluorescent images of endothelial marker VE-cadherin 


























Figure 2-1 C&D. Kallistatin (KS) inhibits TGF-β-induced EndMT. (C) Representative 
immunofluorescent images of endothelial marker CD-31 and (D) mesenchymal marker 
α-SMA in human endothelial cells. Original magnification 200 ✕. Nuclei are 









Figure 2-1 E. Kallistatin (KS) inhibits TGF-β-induced EndMT marker expression. 
Representative western blots of VE-cadherin, CD31 and α-SMA and quantification of 






oxidase stimulates the production of ROS (Yan et al., 2014). Kallistatin treatment 
completely antagonized TGF-β1-induced Nox4 mRNA levels and NADPH oxidase 
activity (Figure 2-2 B&C). Therefore, kallistatin can block TGF-β-induced oxidative stress 
in endothelial cells. 
 
Kallistatin Prevents TGF-β-Induced miR-21 Synthesis, Akt and NF-κB Activation, 
Snail1 Expression, and MMP2 Synthesis and Activation 
Since the miR-21-Akt signaling pathway plays an important role in EndMT, we 
tested whether kallistatin regulates TGF-β-induced EndMT through this pathway. Our 
results showed that TGF-β1 upregulated miR-21 synthesis, but the effect was prevented 
by kallistatin (Figure 2-3 A). Kallistatin also prevented TGF-β1-induced Akt 
phosphorylation (Figure 2-3 B). These results indicate that kallistatin blocks TGF-β-
induced EndMT by inhibiting the miR-21-Akt pathway. Moreover, kallistatin treatment 
attenuated TGF-β1-mediated NF-κB activation (Figure 2-3 C). Since NF-κB leads to the 
activation of the Snail transcription factor, we measured Snail1 mRNA levels. TGF-β1 
significantly induced Snail1 transcription, whereas kallistatin treatment prevented the 
effect (Figure 2-3 D). Furthermore, we analyzed MMP2 synthesis and activation by PCR 
and zymography, respectively. TGF-β1 increased MMP2 mRNA levels and activity, 
which were abolished by kallistatin (Figure 2-3E). These results indicate that kallistatin 
blocks TGF-β-mediated EndMT, in part, by inhibiting the miR-21-Akt-NF-κB pathway, 
Snail1 expression, and MMP2 synthesis and activity. 
 
Kallistatin’s Heparin-Binding Site Is Essential for Preventing TGF-β-Induced miR-















        
 
Figure 2-2.  Kallistatin (KS) inhibits TGF-β-induced ROS formation and NADPH oxidase 
expression and activity in human endothelial cells. (A) Cellular ROS formation 
determined by measuring oxidized fluorescent dye DCF counts. (B) QPCR analysis of 
mRNA levels of NADPH oxidase 4 (Nox4). (C) NADPH oxidase activity determined by 














     
 
Figure 2-3. Kalistatin (KS) inhibits TGF-β-induced miR-21-Akt signaling in human 
endothelial cells. (A) QPCR analysis of miR-21. (B) Representative western blot of 
phospho-Akt and quantitative analysis. (C) NF-κB activity determined by ELISA. (D) 
QPCR analysis of Snail1 mRNA. (E) MMP2 activity was determined by zymography, and 




We analyzed the role of kallistatin’s heparin-binding site in modulating TGF-β1- 
induced miR-21 synthesis and ROS generation. Wild-type kallistatin significantly 
reduced TGF-β1-driven miR-21 expression, whereas heparin-binding site mutant 
kallistatin had no effect (Figure 2-4 A). Likewise, wild-type kallistatin, but not heparin 
mutant kallistatin, inhibited TGF-β1-induced ROS formation (Figure 2-4 B). Moreover, 
kallistatin’s heparin-binding site was found to be essential for abolishing TGF-β1-
mediated Snail1 expression (Figure 2-4 C). Our results demonstrate that kallistatin 
competes with TGF-β1’s ability to bind to heparan sulfate proteoglycans, thus preventing 
TGF-β1-mediated signaling. These new findings indicate that kallistatin’s heparin-binding 
site plays an important role in antagonizing TGF-β-induced miR-21, ROS formation and 
Snail1 expression. 
 
Kallistatin via Its Active Site Stimulates eNOS, SIRT1, and FoxO1 Expression 
We next examined the role of kallistatin’s structural elements on the expression 
of antioxidant genes in endothelial cells. Our results showed that wild-type kallistatin and 
heparin-binding site mutant kallistatin treatment led to a noticeable rise in eNOS, SIRT1 
and FoxO1 mRNA levels, whereas active site-mutant kallistatin had no effect (Figure 2-
5). This finding clearly indicates that the active site of kallistatin is crucial for mediating 
the expression of eNOS, SIRT1 and FoxO1. Moreover, treatment with genistein, a 
tyrosine kinase inhibitor, abolished kallistatin-induced eNOS, SIRT1 and FoxO1 
expression (Figure 2-5). These new results show that kallistatin via its active site 
interacts with a cell surface tyrosine kinase, thus stimulating expression of the 

















Figure 2-4.  Kallistatin via heparin-binding site inhibits miR-21 synthesis, ROS formation 
and Snail 1 expression in human endothelial cells. (A) QPCR analysis of miR-21. (B) 
Cellular ROS formation determined by measuring oxidized fluorescent DCF counts. (C) 
QPCR analysis of Snail1 mRNA. WT-KS: wild-type kallistatin; HM-KS: heparin-binding 









         
Figure 2-5. The active site of kallistatin is essential for increasing the expression of 
eNOS, SIRT1 and FoxO1 via a tyrosine kinase. QPCR analysis of mRNA levels of (A) 
eNOS, (B) SIRT1 and (C) FoxO1 in human endothelial cells. GEN, genistein, a tyrosine 
kinase inhibitor. WT-KS: wild-type kallistatin; HM-KS: heparin-binding site mutant 







             
 
Figure 2-6. Signaling pathway by which kallistatin inhibits EndMT.	Kallistatin’s heparin-
binding site is responsible for suppression of TGF-β-induced miR-21-Akt signaling and 
ROS formation, while its active site is key for stimulating the expression of eNOS, SIRT1 






This study provides new insights into the protective role of kallistatin in EndMT 
and EndMT-associated pathological processes, such as vascular injury and fibrosis. We 
showed that kallistatin prevented EndMT by blocking TGF-β1-induced miR-21 synthesis 
and oxidative stress, and also by directly stimulating the expression of the antioxidant 
genes eNOS, SIRT1 and FoxO1. Moreover, this is the first study to demonstrate that 
kallistatin’s structural elements play crucial roles in the differential regulation of TGF-β 
signaling and eNOS/SIRT1 expression in human endothelial cells. We found that 
kallistatin via its heparin-binding site inhibited TGF-β1-induced miR-21 expression, ROS 
formation, and Snail1 synthesis. Conversely, kallistatin’s active site was observed to be 
essential for stimulating the expression of eNOS, SIRT1 and FoxO1 (Figure 2-6). Both 
eNOS and SIRT1 are responsible for increasing NO production, and NO has been 
shown to be an antioxidant by decreasing ROS levels and NADPH oxidase activity 
(Clancy et al., 1992). Our previous finding has shown that kallistatin administration 
attenuated vascular injury, and cardiac and renal fibrosis in conjunction with reduced 
oxidative stress and increased NO production in animal models with hypertension or 
myocardial infarction (Gao et al., 2008, Shen et al., 2008). Thus, our findings reveal a 
new mechanism that kallistatin, through its structural elements, inhibits vascular injury 
and organ fibrosis by antagonizing EndMT process.  
 
miR-21 is an oncogenic microRNA that is overexpressed in most human tumors, 
and can thus promote tumor growth and progression by acting on multiple target genes 
(Kumarswamy et al., 2011). Increased miR-21 leads to Akt activation, which in turn 
upregulates miR-21 in endothelial cells (Thum et al., 2008). These studies are consistent 
with our findings that TGF-β1 stimulated miR-21 synthesis and Akt 
phosphorylation/activation; however, kallistatin efficiently blocked TGF-β1-mediated 
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effects. Oxidative stress also stimulates miR-21 expresson (Jiang et al., 2014). The 
present study showed that kallistatin not only antagonized TGF-β1-mediated miR-21-Akt 
activation, but also blocked TGF-β1-induced oxidative stress. Therefore, kallistatin can 
attenuate TGF-β-induced EndMT by targeting the miR-21-Akt pathway and oxidative 
stress. 
 
The role of TGF-β-induced Akt-NF-κB activation in the context of EndMT is not 
well understood. In the EMT process, Akt stimulates the nuclear translocation of the NF-
κB complex. NF-κB acts as a transcriptional factor for Snail1 and MMP2 expression 
(Julien et al., 2007, Yan & Boyd, 2007). During EndMT the basal lamina is degraded by 
matrix metalloproteinases, such as MMP2 (Potenta et al., 2008). Snail factors are known 
to repress both VE-cadherin and E-cadherin transcription. Consequently, elevated Snail 
expression can stimulate the loss of endothelial cell–cell junctions. In the present study, 
our results showed that NF-κB was induced by TGF-β1 in endothelial cells undergoing 
EndMT, resulting in elevated Snail1 and MMP2 expression and loss of the endothelial 
marker VE-cadherin. In contrast, kallistatin treatment blocked TGF-β1-mediated miR-21-
Akt activation, leading to suppression of TGF-β-induced NF-κB-Snail1/MMP2 signaling. 
Thus, these results indicate that kallistatin inhibits EndMT through blockade of TGF-β-
induced Akt-NF-κB signaling pathway. 
 
Heparan sulfate proteoglycans are present on the surface of vascular smooth 
muscle cells and endothelial cells (Adhikari et al., 2010, Sarrazin et al., 2011). TGF-β1 is 
a heparin-binding growth factor, and the ability of TGF-β1 to bind to heparan or related 
proteoglycans is the first step to initiate metabolic signals (Chen Q. et al., 2007). Our 
previous studies showed that the heparin-binding site of kallistatin is essential for 
antagonizing signaling pathways mediated by other heparin-binding proteins, such as 
 
 33 
VEGF, TNF-α, and HMGB1 (Miao et al., 2003, Yin et al., 2010, Li et al., 2014). It is likely 
that kallistatin competes with TGF-β1 from binding to heparan sulfate proteoglycans on 
the endothelial cells. Indeed, we showed that kallistatin’s heparin-binding site is essential 
for preventing TGF-β1-induced miR-21-Akt signaling and ROS formation in endothelial 
cells. Therefore, these results provide new information regarding the role of kallistatin’s 
heparin-binding site in antagonizing TGF-β-induced signaling. 
 
eNOS-derived NO is an antioxidant by inhibiting NADPH oxidase activity (Clancy 
et al., 1992, Fujii et al., 1997). In addition to eNOS/NO, both SIRT1 and FoxO1 are 
capable of suppressing ROS formation. SIRT1 can function to deacetylate and activate 
eNOS and FoxO1. FoxO1 is known to promote activation of the antioxidant enzyme 
manganese superoxide dismutase to scavenge ROS (Storz, 2011). Our present finding 
indicates that kallistatin’s active site is responsible for stimulating the expression of the 
antioxidant genes eNOS, SIRT1 and FoxO1, and the effect was blocked by genistein, a 
tyrosine kinase inhibitor. Thus kallistatin’s active site could interact with a tyrosine kinase 
to increase eNOS/SIRT1 expression. The identity of the putative kallistatin-binding 
protein or kallistatin receptor on the endothelial cell surface awaits further investigation. 
 
Taken together, the present study indicates that kallistatin has a novel role in 
inhibiting EndMT, and new functions of kallistatin’s functional domains have been 
identified. Mechanistically, kallistatin through its two structural elements differentially 
regulates miR-21, oxidative stress and eNOS expression. Kallistatin’s heparin-binding 
site plays an important role in suppressing miR-21-Akt signaling and ROS formation, 
whereas its active site is key for stimulating the expression of eNOS, SIRT1 and FoxO1. 
Moreover, kallistatin via its active site interacts with a tyrosine kinase to stimulate eNOS 
synthesis, which can lead to NO formation and reduced oxidative stress. Thus, kallistatin 
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exerts potent antioxidant activity by dual mechanisms: (1) blocking TGF-β-induced 
oxidative stress, and (2) increasing eNOS/SIRT1/FoxO1 levels. These new findings 
shed light on the pleiotropic functions and mechanisms of kallistatin in the potential 














TO DETERMINE THE ROLE AND MECHANISM OF KALLISTATIN IN 






Kallistatin protects against vascular injury by inhibiting oxidative stress in 
hypertensive rats and enhancing the mobility and function of endothelial progenitor cells 
(EPCs). We further determined the role and mechanism of kallistatin in vascular 
senescence and aging using cultured EPCs, streptozotocin (STZ)-induced diabetic mice, 
and Caenorhabditis elegans (C. elegans). Human kallistatin significantly decreased 
TNF-α-induced EPC senescence, as indicated by reduced senescence-associated β-
galactosidase activity, plasminogen activator inhibitor-1 expression, and elevated 
telomerase activity. Kallistatin blocked TNF-α-induced superoxide levels, NADPH 
oxidase activity, miR-21 expression and cell cycle inhibitor p16INK4a synthesis. The 
microRNA (miR)-34a-SIRT1 axis is an important signaling in regulating senescence. 
Kallistatin prevented TNF-α mediated inhibition of SIRT1, eNOS, and catalase, and 
directly stimulated the expression of these antioxidant enzymes. Importantly, kallistatin 
inhibited miR-34a synthesis, whereas miR-34a overexpression abolished kallistatin-
induced SIRT1/eNOS expression and anti-senescence activity. Kallistatin via its active 
site inhibited miR-34a, and stimulated SIRT1 and eNOS synthesis in EPCs, which was 
abolished by genistein, indicating an event mediated by tyrosine kinase. Moreover, 
kallistatin administration attenuated aortic senescence, oxidative stress, associated with 
reduced miR-34a and miR-21 synthesis and increased SIRT1, eNOS, and catalase 
levels in STZ-induced diabetic mice. Furthermore, kallistatin treatment reduced 
superoxide formation and improved wild-type C. elegans survival under oxidative or heat 
stress, although kallistatin’s protective effect was abolished in miR-34 or sir-2.1 (SIRT1 
homolog) mutant C. elegans. Kallistatin inhibited miR-34, but stimulated sir-2.1 and sod-
3 synthesis in C. elegans. These in vitro and in vivo studies provided significant insights 
into the role and mechanism of kallistatin in vascular senescence and aging by 




EPCs are a major contributor to vascular repair, and can be derived from bone 
marrow, circulating mononuclear cells, and cord blood (Lin et al., 2000, Reyes et al., 
2002). Circulating EPCs are the most important cell population for the replenishment of 
damaged or senescent endothelial cells. Advanced aging is a major risk factor for 
suppressed EPC function (Williamson et al., 2012). Senescent or impaired EPCs 
contribute to endothelial dysfunction, which is a predictor of cardiovascular 
diseases(Heiss et al., 2005). Type I diabetes is one of cardiovascular-associated 
diseases characterized by reduced EPC numbers and vascular repair (Loomans et al., 
2004). Moreover, the nematode C. elegans has a number of distinct advantages that are 
useful for understanding the molecular basis of organismal dysfunction underlying age-
related diseases. Due to its short life cycle (3.5 days) and conserved longevity genes 
from worm to human (Zhou et al., 2011). C. elegans is an ideal model for investigating 
the aging process. Consequently, EPCs, STZ-induced diabetic mice, and C. elegans are 
valuable models for examining the mechanisms of vascular senescence and aging. 
 
Oxidative stress is a key inducer of endothelial senescence, with the 
inflammatory cytokine TNF-α being the main contributor to reactive oxygen species 
(ROS) production (Chen et al., 2008). Upregulation of antioxidant proteins, such as 
endothelial nitric oxide synthase (eNOS), sirtuin 1 (SIRT1), catalase, and manganese 
superoxide dismutase (MnSOD), has been shown to protect against oxidative stress-
mediated insults (Wassmann et al., 2004, Ota et al., 2010). eNOS maintains the redox 
state of endothelial cells and promotes vasorelaxation through NO production 
(Forstermann & Sessa, 2012). SIRT1 is a conservative longevity gene from yeast to 
human, and accounts for vascular homeostasis by activating many antioxidant enzymes, 
such as eNOS, catalase, and MnSOD, to diminish ROS (Kitada et al., 2016). 
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Conversely, growing evidence has shown that miR-34a is a senescence promoter, as it 
inhibits SIRT1 through a miR-34a-binding site within the 3’ UTR of SIRT1 (Zhao et al., 
2010). Furthermore, miR-21, a tumor inducer, is also involved in EPC senescence (Zhu 
S. et al., 2013). The antioxidant enzymes and pro-senescence miRNAs underlie the 
molecular basis for endothelial senescence and aging-associated diseases. Therefore, 
exploration of effective molecules or compounds that stimulate longevity gene 
expression and inhibit the effects of negative regulators may lead to a prospective 
enhancement of vascular integrity and lifespan. 
 
Kallistatin treatment increases circulating EPC number and reduces aortic 
oxidative stress in hypertensive rats, whereas kallistatin deficiency decreases EPC 
levels and exacerbates oxidative vascular injury (Liu Y. et al., 2012, Gao et al., 2014). In 
addition, kallistatin promotes vascular repair by enhancing the viability, migration, and 
function of EPCs (Gao et al., 2014). Kallistatin, via NO stimulation, reduces TNF-α 
induced superoxide production and NADPH oxidase activity in endothelial cells (Shen et 
al., 2010). Moreover, in Chapter II we showed that kallistatin prevented endothelial–
mesenchymal transition (EndMT) by inhibiting TGF-β-induced miR-21 and increasing 
SIRT1 synthesis (Guo et al., 2015). However, whether kallistatin through regulating miR-
34a-SIRT1 pathway affects endothelial senescence has not been explored, in this study 
we investigated the potential role of kallistatin in vascular senescence and aging, using 




Materials and Methods 
Isolation and Culture of EPCs 
EPCs were isolated from human umbilical cord blood as described (Gao et al., 
2014). The study was approved by the Medical University of South Carolina Human 
Research (Pro00017277). EPCs were isolated by density gradient centrifugation using 
Ficoll-Paque PLUS (GE Healthcare,) and cultured in endothelial basal medium with 10% 
fetal bovine serum and supplements (Lonza). 
 
Senescence-associated β-Galactosidase Staining 
EPCs at 80% confluency in 12-well plates were pre-incubated with kallistatin (1 
µM) for 30 min and then treated with TNF-α (10 ng/mL) for 6 days. The senescence 
phenotype was detected using the β-galactosidase staining kit (Cell Signaling). The 
number of positive senescence-associated β-galactosidase (SA-β-gal) cells was 
observed by light microscopy (Olympus CK40) in 10 randomly chosen low-power fields 
(✕ 200) and expressed as a percentage of counted cells. 
 
Telomerase Activity Assay 
EPCs were pre-incubated with or without kallistatin (1 µM) for 30 min prior to the 
addition of TNF-α (10 ng/mL) for 24 h. Cells were lysed with non-denaturing lysis buffer. 
Telomerase activity was measured using TRAPEZE RT telomerase detection kit (EMD 
Millipore). 
 
NADPH Oxidase Activity Assay 
The enzymatic activity of NADPH oxidase was assessed as described in Chapter 




Detection of Superoxide Formation 
Cellular ROS generation was detected using the peroxide-sensitive fluorescent 
probe 2’, 7’-dichlorodihydrofluorescein diacetate (DCFH-DA; 10 µM, Sigma). To 
determine the role of PI3K-Akt-eNOS pathway, EPCs were pretreated with PI3K inhibitor 
LY294002 (5 µM) or iNOS inhibitor L-NAME (100 µM) for 30 min in prior to kallistatin 
treatment. To quantify ROS levels, EPCs were seeded onto a 96-well fluorescence plate 
and treated as above. Relative fluorescence	was measured using the fluorescence plate 
reader at 485-nm excitation and 535-nm emission. Superoxide levels in aortas were 
determined by red fluorescent probe dihydroethidium (DHE; 3 µM Sigma) incubation at 
37°C for 30 min at dark. For ROS staining in C. elegans, worms were washed, incubated 
with 3 µM DHE for 30 min and anesthetized with 5 mM levamisole (Sigma). C. elegans 
were then transferred to glass slides, sealed with 70% glycerol, and imaged with a 
fluorescence microscope (Olympus CK40). Fluorescence intensity was analyzed using 
IMAGE J software (National Institutes of Health). 
 
RNA Extraction and qRT-PCR 
Total RNA was extracted and reversely transcribed as in Chapter II. RT primers 
for miRNAs were used as follows: U6 for EPCs and mice, has-miR-34a and has-miR-21 
for EPCs, mmu-miR-34a-3p and mmu-miR-21 for mice, and U18 and cel-miR-34 for C. 
elegans. Human 18S was internal control gene for quantifying mRNA expression. Mouse 
or C. elegans GAPDH was used as internal control gene for quantifying mRNA 
expression. The following primers were used: 18S (Hs99999901_s1), U6 snRNA 
(001973), p16INK4a (Hs00923894_m1), has-miR-34a (002316), eNOS (Hs01574659_m1), 
SIRT1 (Hs01009006_m1), catalase (Hs00156308_m1), PAI-1 (Hs01126606_m1), 
GAPDH (Mm99999915_g1), eNOS (Mm00435217_m1), SIRT1 (Mm00490758_m1), 
catalase (Mm00437992_m1), U18 (001764), miR-34 (Ce241995_mat), GAPDH 
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(Ce02425762_m1), sir-2.1 (Ce02459018_g1), and sod-3 (Ce02404515_g1). Data were 
analyzed with 2-ΔCt value calculation using control genes for normalization. 
 
Western Blot  
Proteins from cell lysates or tissue lysates were separated by SDS-PAGE and 
immunoblotted as previously described in Chapter II. Primary antibodies were anti-
SIRT1, anti-eNOS, anti-β-actin, and anti-GAPDH. Chemiluminescence was detected by 
the ECL-plus kit (GE Healthcare).  
 
miRNA Transfection 
For miR-34a overexpression, EPCs were transfected with 5 pM of miR- 34a 
mimic or control miRNA (Fisher Scientific) with Lipofectamine RNAiMAX reagent (Fisher 
Scientific) for 12 h according to the manufacturer’s protocol. 
 
Diabetic Mouse Experiments 
All procedures complied with the standards for care and use of animal subjects 
as stated in the Guide for the Care and Use of Laboratory Animals. The protocol for all 
animal studies was approved by the Institutional Animal Care and Use Committee at the 
Medical University of South Carolina. Male wild-type C57/BL6 mice (7–8 weeks of age) 
were purchased from Harlan. Mice (male, 12-week-old) were fasted for 16 h and 
subjected to 6-day continuous intraperitoneal injections of streptozotocin (STZ, 60 
mg/kg; Sigma) to induce type 1 diabetes. Sodium citrate buffer alone (0.1 M, pH 4.5) 
was injected in control animals. Mice with blood glucose > 250 mg/dL were considered 
diabetic and used in this study. A total of 18 mice were randomly assigned to three 
groups: control group (n = 6), diabetes group (n = 6), and diabetes + kallistatin group (20 
mg/kg body weight, n = 6). Mice were injected with kallistatin intraperitoneally every 2 
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days after verification of diabetes. One week after kallistatin injection, the thoracic aorta 
was collected for histological analysis or gene expression analysis. 
 
C.elegans Treatments 
Wild-type (N2) C. elegans, sir-2.1 mutant strain VC199 (ok434), miR-34 mutant 
strain (gk437), and SOD-3::GFP strain CF1553 (muIs84) were obtained from the 
Caenorhabditis Genetics Center. C. elegans were cultured and maintained at 25°C on 
nematode growth medium (NGM) seeded with E. coli OP50. N2 worms were treated with 
different concentrations of kallistatin (1 or 5 µM) from L4 stage (adult) for 3 days. Total 
RNA was extracted for QPCR. 
 
Stress Resistance Assay 
For heat-shock assay, age-synchronized N2 L4 worms (n = 30) were pre-
incubated with kallistatin (1 or 5 µM), and were cultured with daily exchanged fresh 
medium plates. Two days later, adult worms were exposed at 35°C for 6 h. The survival 
of worms was recorded after thermal stress by touching or tapping as monitored under 
microscope (AmScope). For oxidative stress resistance assay, age-synchronized N2 L4 
worms (n = 50) were pre-incubated with or without kallistatin (1 or 5 µM). Next, the three 
groups were separately transferred to NGM plates containing 2 mM paraquat (Sigma). 
Survival of the worms was scored daily until the death of last worm. 
 
Statistical Analysis 
Data are expressed as means ± SE of three independent experiments. Student t-
test and analysis of variants were used to assess differences. Survival curves between 
treatment groups were compared using the nonparametric log-rank test. A value of P < 




Kallistatin Inhibits TNF-α-Induced Cellular Senescence in EPCs 
To identify the effect of kallistatin on cellular senescence in cultured EPCs, we 
evaluated three senescent markers, including SA-β-gal activity, plasminogen activator 
inhibitor-1 (PAI-1) synthesis, and telomerase activity. Six days’ treatment of TNF-α 
caused marked increased SA-β-gal positive cell numbers compared with the control 
group, whereas pre-incubation with purified human kallistatin significantly reduced TNF-
α-induced SA-β-gal-positive cells. Kallistatin alone had no effect on EPC senescence 
(Figure 3-1 A). Quantitative analysis of SA-β-gal staining confirmed these results (Figure 
3-1 B). TNF-α increased PAI-1 synthesis, whereas kallistatin significantly suppressed 
PAI-1 expression with or without TNF-α treatment (Figure 3-1 C). Moreover, kallistatin 
prevented TNF-α-mediated suppression of telomerase activity in EPCs (Figure 3-1 D). 
These results indicate that kallistatin is capable of blocking TNF-α-induced EPC 
senescence.  
 
Kallistatin Inhibits TNF-α-Induced Oxidative Stress, and miR-21 and p16INK4a 
Synthesis 
To further determine kallistatin’s effect on senescence-associated oxidative 
stress in EPCs, fluorescence probe DCFH-DA was used to detect cellular ROS 
formation. Representative images show that kallistatin inhibited TNF-α-induced 
accumulation of cellular ROS in EPCs, and kallistatin’s effect was abolished by 
pretreatment with the PI3K inhibitor LY294002 or the NOS inhibitor L-NAME (Figure 3-2 
A). Quantitative analysis verified kallistatin’s inhibitory effect on ROS formation (Figure 
3-2 B). Likewise, kallistatin suppressed TNF-α-induced NADPH oxidase activity, which 
was again abolished by LY294002 or L-NAME (Figure 3-2 C). Kallistatin alone had no 
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Figure 3-1. Kallistatin (KS) inhibits TNF-α-induced EPC senescence. (A) Representative 
images of senescence-associated β-gal staining in EPCs. (B) Quantification of positive 
gal staining cells. (C) QPCR analysis of PAI-1. (D) QPCR detection of telomerase 
activity. n = 3. *P < 0.05 vs. control, #P < 0.05 vs. TNF-α group.   
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Figure 3-2 A-C. Kallistatin (KS) inhibits TNF-α-induced oxidative stress in EPCs. (A) 
Representative images of ROS formation using fluorescent probe DCFH-DA. (B) 
Quantification analysis of ROS production. (C) NADPH oxidase activity determined by 






TNF-α-induced oxidative stress via activation of the PI3K-Akt-eNOS signaling pathway. 
Kallistatin also antagonized TNF-α-induced miR-21 synthesis (Figure 3-2 D). Moreover, 
kallistatin markedly reduced the expression of p16INK4a, a cyclin-dependent kinase 
inhibitor known to be a senescence-associated inducer of cell cycle arrest (Figure 3-2 
E). Collectively, these results indicate that kallistatin inhibits TNF-α-induced oxidative 
stress, and miR-21 and p16INK4a synthesis. 
 
Kallistatin Prevents TNF-α-Mediated Inhibition of SIRT1, eNOS, and Catalase and 
Stimulates Antioxidant Gene Expression 
We next determined the effect of kallistatin on the antioxidant genes of SIRT1, 
eNOS, and catalase. Kallistatin treatment increased SIRT1 protein levels, as determined 
by western blot (Figure 3-3 A, top panel). Moreover, kallistatin reversed TNF-α-mediated 
inhibition of SIRT1, eNOS, and catalase expression (Figure 3-3 A–C). Additionally, 
kallistatin alone stimulated the synthesis of these antioxidant enzymes (Figure 3-3 A–C). 
Therefore, kallistatin not only prevented TNF-α-mediated inhibition of eNOS, SIRT1, and 
catalase, but also increased the expression levels of antioxidant enzymes. 
 
Kallistatin Stimulates Antioxidant Gene Expression through miR-34a Inhibition 
 As miR-34a is a key senescence mediator, we examined kallistatin’s effect on 
miR-34a. Our results showed that kallistatin markedly inhibited miR-34a synthesis in 
EPCs (Figure 3-4 A). To further determine the role of miR-34a in kallistatin-mediated 
stimulation of antioxidant genes, miR-34a was overexpressed by transfection of miR-34a 
mimic to EPCs. miR-34a overexpression suppressed SIRT1, eNOS, and catalase 
expression compared to the mimic control group, and also abolished kallistatin’s 
stimulatory effect on these antioxidant genes (Figure 3-4 B–D). Moreover, miR-34a 




































Figure 3-2 D&E. Kallistatin (KS) inhibits TNF-α-induced miR-21 and p16INK4a synthesis 
in EPCs. QPCR analysis of (D) miR-21 and (E) p16INK4a gene expression. n = 3. *P < 
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Figure 3-3. Kallistatin (KS) stimulates SIRT1, eNOS, and catalase expression and 
prevents TNF-α-mediated inhibition of these genes in EPCs. (A) Representative western 
blot of SIRT1 and QPCR analysis of SIRT1 mRNA levels. (B) QPCR of eNOS mRNA 
levels. (C) QPCR analysis of catalase mRNA levels.  n = 3. *P < 0.05 vs. control, # P < 







                           




C                                                                  D   
                                                          
Figure 3-4 A-D. Kallistatin (KS) though inhibiting miR-34a upregulates antioxidant genes 
SIRT1, eNOS and catalase in EPCs. QPCR analysis of (A) miR-34a in kallistatin treated 
EPCs. QPCR analysis of  (B) SIRT1, (C) eNOS and (D) catalase mRNA levels in mimic 






staining (Figure 3-4 E). These results indicate that kallistatin, by inhibiting miR-34a 
synthesis, prevents miR-34a-mediated inhibition of SIRT1 and eNOS expression to 
alleviate EPC senescence. 
 
Kallistatin’s Active site Is Essential for Stimulating Antioxidant Gene Expression: 
Role of Tyrosine Kinase 
To determine which functional domain of kallistatin is essential for the regulation 
of miR-34a-SIRT1 pathway, three types of kallistatin, including wild-type kallistatin, 
heparin-binding site mutant kallistatin, and active site mutant kallistatin, were used. We 
found that both wild-type kallistatin and heparin-binding site mutant kallistatin effectively 
inhibited miR-34a synthesis and elevated SIRT1 and eNOS mRNA levels in EPCs, but 
active site mutant kallistatin had no such effects (Figure 3-5 A–C). The results indicate 
that kallistatin’s active site is essential for modulating the expression of miR-34a, SIRT1, 
and eNOS in EPCs. Moreover, genistein, a tyrosine kinase inhibitor, blocked wild-type 
kallistatin’s effect in modulating miR-34a, SIRT1, and eNOS synthesis (Figure 3-5 A–C), 
implicating the involvement of a tyrosine kinase. Thus, kallistatin’s active site is critical 
for downregulation of miR-34a and upregulation of SIRT1 and eNOS. 
 
Kallistatin Attenuates Aortic Senescence, Superoxide Formation Associated with 
Decreased miR-34a and miR-21 Synthesis and Increased SIRT1, eNOS, and 
Catalase Levels in Diabetic Mice 
We further determined kallistatin’s in vivo effect on vascular senescence and 
oxidative stress in aortas of STZ-induced diabetic mice. Aortic senescence, identified by 
SA-β-gal staining, was increased in diabetic mice compared to control mice, while 
kallistatin treatment prevented STZ-induced effect (Figure 3-6 A). Moreover, higher 
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Figure 3-4 E. miR-34a mimic abolishes the anti-senescent effect of kallistatin (KS) in 
EPCs. (E) Representative images of positive SA-β-gal staining in mimic control and miR-













Figure 3-5. The active site of kallistatin is essential for modulating miR-34a, eNOS, and 
SIRT1 synthesis through interacting with a tyrosine kinase in EPCs. QPCR analysis of 
(A) miR-34a, (B) SIRT1 and (C) eNOS. GEN: genistein, a tyrosine kinase inhibitor. 
WTKS: wild-type kallistatin; HMKS: heparin-binding site mutant kallistatin; AMKS: active 





of STZ-induced diabetic mice, but this observation was reversed by kallistatin 
administration (Figure 3-6 B&C). Furthermore, STZ induced a significant increase of 
miR-34a and miR-21 synthesis, as well as reduced SIRT1, eNOS, and catalase mRNA 
levels in aortas of diabetic mice compared to control mice, while kallistatin administration 
reversed STZ-mediated effect (Figure 3-6 D–H). Consistently, aortic SIRT1 and eNOS 
protein levels were markedly reduced in diabetic mice compared to control mice, but 
were restored by kallistatin administration, as determined by western blot (Figure 3-6 
I&J). Consistent with the results derived from cultured EPCs, kallistatin treatment 
protects against vascular aging and oxidative	stress in diabetic mice by decreasing miR-
34a and miR-21 synthesis and increasing SIRT1, eNOS, and catalase levels. 
 
Kallistatin Enhances Wild-type C. elegans Lifespan under Oxidative or Heat Stress 
Independent of the Presence of miR-34 and sir-2.1 
As stress conditions impair C. elegans longevity and induce premature 
senescence, we investigated the effect of kallistatin on C. elegans survival under 
oxidative or thermal stress. Paraquat was used to induce oxidative damage in three 
strains of C. elegans, including wild-type (N2), miR-34 mutant, and sir-2.1 (SIRT1 
analogue) mutant worms. Representative images showed that kallistatin (1 or 5 µM) 
markedly reduced paraquatinduced superoxide formation in C. elegans, as identified by 
red fluorescence probe DHE, and the result was confirmed by quantitative analysis 
(Figure 3-7 A). Moreover, the mean lifespan of wild-type C. elegans was 13.3 ± 0.9 days 
under normal condition at 25°C, but was shortened to 7.7 ± 0.3 days under paraquat- 
induced oxidative stress. Pretreatment with 1 or 5 µM kallistatin reduced the sensitivity to 
paraquat and increased mean lifespan of C. elegans by 5.8% or 20.5%	(8.2 ± 0.3 or 9.3 
± 0.4 days), respectively (Figure 3-7 B). However, kallistatin treatment had no effect on 

































Figure 3-6 A-D. Kallistatin (KS) attenuates vascular aging, superoxide production, and 
miR‐21 synthesis in aortas of diabetic mice. (A) Representative images of SA‐β‐gal 
staining in thoracic aortas from control mice, STZ‐induced diabetic mice, and KS‐treated 
diabetic mice. (B) Representative images of superoxide formation labeled by red 
fluorescence dye hydroethidine (DHE). (C) NADPH oxidase activity measured by 
lucigenin chemiluminescence assay in mouse aortas. (D) QPCR analysis of miR-21 in 
mouse aorta. STZ: streptozotocin. n=6. *P < 0.05 vs. control group; #P < 0.05 vs. STZ 
group. 
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Figure 3-6 E-J. Kallistatin (KS) inhibits miR-34a synthesis and stimulates antioxidant 
gene expression in the aorta of diabetic mice. QPCR analysis of (E) miR-34a, (F) SIRT1, 
(G) eNOS and (H) catalase in mouse aorta. Representative western blots of (I) SIRT1 
and (J) eNOS in mouse aorta. STZ: streptozotocin. n=6. *P < 0.05 vs. control group; # P 
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Figure 3-7 A. Kallistatin (KS) inhibits paraquat-induced superoxide formation in C. 
elegans. (A) Representative images of superoxide formation in wild-type C. elegans. 
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Figure 3-7 B-D. Kallistatin (KS) enhances C. elegans longevity under oxidative stress. 
Survival curves of (B) wild-type (N2) strain, (C) miR-34 mutant (gk437) and (D) sir-2.1 
mutant (ok434). n=50 worms per group.  
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The results indicate that miR-34 and sir-2.1 are essential for kallistatin-mediated C. 
elegans longevity under oxidative stress. Kallistatin significantly increased C. elegans 
thermo-tolerance at 35 °C. Wild-type worm survival rate was 38.9 ± 3.9% under thermal 
condition, but kallistatin treatment at 1 and 5 lM markedly enhanced worm survival to 
63.3 ± 4.4% and 72.1 ± 10.5%, respectively (Figure 3-7 E). However, kallistatin (1 or 5 
µM) had no effect on the survival of miR-34 mutant or sir-2.1 mutant worms at 35 °C 
(Figure 3-7 F&G). Similar to oxidative stress, these results confirm that kallistatin 
promotes C. elegans survival under heat stress via regulating miR-34 and sir-2.1. 
Moreover, kallistatin treatment inhibited miR-34, but increased sir-2.1 and sod-3 
(MnSOD analogue) synthesis (Figure 3-7 H–J). Likewise, SOD-3 protein levels were 
elevated by kallistatin treatment, as evidenced using SOD-3::GFP co-expression C. 
elegans as a sod-3 indicator (Figure 3-7 K). Collectively, kallistatin inhibits miR-34 
synthesis and stimulates sir-2.1 and sod-3 levels in C. elegans, and the regulatory 
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Figure 3-7 E-G. Kallistatin (KS) enhances C. elegans survival under heat stress. 
Average survival ratios of (E) wild-type (N2), (F) miR-34a mutant (gk437) and (G) sir-2.1 
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Figure 3-7 H-K. Kallistatin inhibits miR-34 but stimulates sir-2.1 and sod-3 expression 
in C. elegans. QPCR analysis of (H) miR-34, (I) sir-2.1, (J) sod-3 mRNA levels. (K) 
Representative images of SOD3 expression in SOD-3::GFP C. elegans. n=100 worms 













Figure 3-8. Signaling mechanism by which kallistatin inhibits vascular senescence and 
aging. Kallistatin via its heparin-binding site antagonizes TNF-α mediated miR-21 
synthesis, ROS formation, PAI-1 and p16INK4a expression, and telomerase activity in 
EPCs. Kallistatin via its active site prevents miR‐34a‐mediated inhibition of antioxidant 
genes SIRT1, eNOS, and catalase and SOD-3. The tyrosine kinase inhibitor, genistein, 




This study demonstrates a novel role of kallistatin in vascular senescence and 
aging using cultured EPCs, STZ-induced diabetic mice, and C. elegans. Recombinant 
human kallistatin treatment significantly reduced EPC senescence by blocking TNF-α-
induced oxidative stress, and decreased the senescence markers, PAI-1, miR-21, and 
p16INK4a, but increased telomerase activity. Kallistatin via its active site inhibited miR- 
34a and stimulated SIRT1, eNOS, and catalase synthesis, whereas overexpression of 
miR-34a abolished kallistatin’s effects on these antioxidant enzymes and anti-
senescence action. Moreover, kallistatin suppressed miR-34a and stimulated SIRT1 and 
eNOS expression, through interaction with cell surface tyrosine kinase in EPCs. 
Likewise, kallistatin administration in STZ-induced diabetic mice alleviated aortic 
senescence and oxidative stress associated with reduced miR-34a and miR-21 
synthesis and increased SIRT1, eNOS, and catalase levels. Moreover, kallistatin 
prolonged wild-type C. elegans lifespan under heat or oxidative stress conditions by 
inhibiting miR-34, and stimulating sir-2.1 (SIRT1). These in vitro and in vivo studies 
support the view that kallistatin protects against vascular senescence and aging by 
preventing miR-34a-mediated inhibition of SIRT1 and eNOS, thus inhibiting oxidative 
stress. The signaling mechanisms of kallistatin’s anti-senescence actions are depicted in 
Figure 3-8. 
 
Oxidative stress is the leading cause of endothelial dysfunction and senescence. 
The inflammatory factor TNF-α has the ability to potentiate ROS generation by activating 
NADPH oxidase on the endothelial cell surface (Yoshida & Tsunawaki, 2008). 
Conversely, eNOS reduces intracellular superoxide levels through NO formation, which 
inhibits NADPH oxidase activity (Fujii et al., 1997). In this study, we demonstrated that 
kallistatin inhibited TNF-α-induced oxidative stress via activation of the PI3K-Akt-eNOS 
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signaling pathway, as kallistatin’s effect was blocked by LY294002 and L-NAME. 
Likewise, our previous report showed that kallistatin antagonized TNF-α-mediated 
apoptosis through increased Akt-eNOS phosphorylation in endothelial cells (Shen et al., 
2010). Kallistatin also promoted the proliferation and migration of EPCs via activation of 
Akt-eNOS signaling pathway (Gao et al., 2014). Thus, it is likely that kallistatin 
antagonizes TNF-α-induced senescence by activation of Akt and eNOS phosphorylation 
in EPCs. In addition, miR-21 modulates ROS production in several cell types (Zhang et 
al., 2012, Jiang et al., 2014), and kallistatin inhibited TGF-β induced miR-21 synthesis 
and oxidative stress in endothelial cells (Guo et al., 2015). Our current data showed that 
kallistatin also blocked TNF-α-mediated miR-21 expression and ROS production in 
EPCs. Kallistatin’s vasoprotective effect has been shown in animal models of salt-
induced hypertension, renal injury, and chronic myocardial infarction through inhibiting 
oxidative stress (Gao et al., 2008; Shen et al., 2008, 2010). Consistently, our current 
study showed that kallistatin attenuated vascular aging and oxidative stress in 
conjunction with increased antioxidant protein levels in the aortas of STZ-induced 
diabetic mice. Collectively, these studies indicate that kallistatin, via inhibiting oxidative 
stress, protects against vascular senescence. 
 
The longevity factor SIRT1 is a NAD+-dependent histone deacetylase, and high 
levels of SIRT1 were shown to inhibit oxidative stress and DNA damage (Alcendor et al., 
2007). SIRT1 activates antioxidant enzymes, including catalase and MnSOD, by 
stimulating the FOXO transcription factors (Brunet et al., 2004). Through a positive 
feedback loop, SIRT1 activates eNOS, which in turn activates SIRT1 (Ota et al., 2010). 
Importantly, SIRT1 is highly expressed during angiogenesis in endothelial cells, and 
disrupting SIRT1 abrogates vascular endothelial homeostasis and remodeling (Potente 
et al., 2007). Our results indicate that kallistatin treatment stimulated the expression of 
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SIRT1 and its downstream antioxidant enzymes eNOS and catalase, as well as 
antagonized TNF-α-mediated inhibition of SIRT1, eNOS, and catalase synthesis in 
cultured EPCs. Similarly, kallistatin elevated the levels of these antioxidant enzymes in 
the aortas of STZ-induced diabetic mice. In C. elegans, SIRT1 homolog sir-2.1 and 
MnSOD homolog sod-3 were also increased upon kallistatin treatment, whereas sir-2.1 
mutant abolished kallistatin mediated stress resistance. Collectively, these combined 
results reveal a critical role of SIRT1 in mediating kallistatin’s effect on oxidative stress 
and vascular aging. 
 
The role of miR-34a in regulating cell senescence, differentiation, and vitality has 
been extensively highlighted in a wide variety of cells (Tazawa et al., 2007, Zhao et al., 
2010). miR-34a triggers senescence partly through genetic inhibition of SIRT1 in EPCs 
(Zhao et al., 2010). This observation inspired us to explore the potential role of kallistatin 
in modulating miR-34a-dependent SIRT1 expression in EPCs. Our results showed that 
kallistatin significantly suppressed miR-34a synthesis, but stimulated eNOS, SIRT1, and 
catalase expression in EPCs and aortas of diabetic mice. Intriguingly, overexpression of 
miR-34a by transfection of miR-34a mimic abolished kallistatin-induced antioxidant gene 
expression. Moreover, miR-34a mimic markedly induced EPC senescence; however, 
kallistatin had no effect on miR-34a-induced EPC senescence. These findings indicate 
that kallistatin’s anti-senescent effect is mediated by suppressing miR-34a synthesis in 
EPCs. Furthermore, genistein, a tyrosine kinase inhibitor, blocked kallistatin’s effects on 
the expression of miR-34a, eNOS, and SIRT1, which is partially in consistent with our 
previous findings in human endothelial cells (Guo et al., 2015). The results reveal that 
kallistatin, through interacting with tyrosine kinase, downregulates miR-34a leading to 




Kallistatin via its two structural elements regulates differential signaling pathways 
(Chao et al., 2016). Kallistatin via its heparin-binding site antagonized TNF-α-induced 
NF-κB activation and thus inflammatory gene expression (Yin et al., 2010). Our current 
finding indicates that kallistatin also antagonized	 TNF-α-induced senescence and 
oxidative stress in EPCs. Kallistatin blocks TNF-α-induced endothelial senescence 
mediators, miR-21 and p16INK4a. Likewise, kallistatin markedly downregulated TNF-α-
induced expression of PAI-1, a pro-atherogenic factor and an endothelial aging marker. 
Furthermore, kallistatin reversed TNF-α-mediated inhibition of telomerase, which is 
responsible for maintaining telomere length and cellular integrity. Consistently, our 
recent report showed that circulatory kallistatin levels are positively associated with 
leukocyte telomere length in humans (Zhu et al., 2016), indicating a potential role of 
kallistatin in maintaining telomere length. Therefore, kallistatin via its heparin-binding site 
blocks TNF-α-mediated effects in EPCs. Meanwhile, kallistatin’s active site is essential 
for stimulating eNOS and SIRT1 in endothelial cells (Guo et al., 2015). In this study, we 
showed that kallistatin through its active site inhibited miR-34a synthesis and stimulated 
eNOS and SITR1 expression in EPCs. Therefore, kallistatin, through its two functional 
domains, displays anti-senescence actions by blocking TNF-α-induced effects, and 
preventing miR-34amediated inhibition of SIRT1 and eNOS.  
 
The STZ-induced diabetic mouse is a popular model for studying vascular injury 
and aging. Kallistatin levels are markedly reduced in vitreous fluids of patients with 
diabetic retinopathy and in the retinas in STZ-induced diabetic rats (Ma et al., 1996, 
Hatcher et al., 1997). Decreased kallistatin levels are also observed in the kidney of 
STZ-induced diabetic mice and in TNF-α-induced senescent human EPCs. Moreover, 
endogenous kallistatin plays a protective role in multi-organ function, as depletion of 
kallistatin by neutralizing antibody injection augmented cardiovascular and renal 
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damage, and increased oxidative stress, inflammation, and endothelial cell loss in 
hypertensive rats (Liu et al., 2012). Furthermore, kallistatin treatment exerts 
renoprotective effects in diabetic nephropathy by suppressing ROS and inflammatory 
gene expression in mice (Yiu et al., 2016). Accumulating evidence indicates that 
kallistatin acts as a potent antioxidant and anti-inflammatory agent in cultured cells and 
animal models (Gao et al., 2008; Shen et al., 2010; Yin et al., 2010; Li et al., 2014; Guo 
et al., 2015). As oxidative endothelial injury and aging are observed in	 diabetes, 
kallistatin may have a role in protection against vascular damage in diabetic disease. 
Indeed, our current study showed that kallistatin treatment in STZ-induced diabetic mice 
attenuated aortic senescence and superoxide formation, in association with reduced 
miR-34a and miR-21, and increased SIRT1, eNOS, and catalase synthesis. The findings 
in diabetic mice support the concept that kallistatin plays a protective role in vascular 
injury and aging by regulating miR-34a, SIRT1, and eNOS synthesis. 
 
C. elegans is a prominent model for aging study, as pathways mediating 
longevity and metabolism are conserved from C. elegans to mammals. Heat or oxidative 
stress induces elevated levels of ROS and cellular damage in C. elegans, leading to 
accelerated aging (Rodriguez et al., 2013). In this study, we demonstrated that kallistatin 
treatment improved C. elegans lifespan or survival under oxidative stress or heat 
conditions. Previous studies showed that miR-34 loss-offunction mutation or sir-2.1 
(SIRT1 homolog) overexpression in C. elegans markedly delayed the age-related 
physiological decline and prolonged lifespan in response to stress conditions 
(Tissenbaum & Guarente, 2001, Yang et al., 2013). Herein, we showed that kallistatin 
treatment inhibited miR-34 and stimulated sir-2.1 and sod-3 synthesis in wild-type C. 
elegans. Kallistatin’s protective effect in the longevity of wild-type C. elegans was 
abolished in miR-34 or sir-2.1 mutant C. elegans under stress conditions. Consistent 
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with the findings in EPCs and diabetic mice, these results further verify that kallistatin’s 
anti-aging effect is dependent on miR-34 inhibition and sir-2.1 (SIRT1) activation. 
Collectively, these findings provide significant insights regarding the mechanism of 
kallistatin in regulating the aging process via miR-34a-SIRT1 pathway. 
 
In conclusion, this is the first study to demonstrate the protective role of kallistatin 
in vascular senescence and aging. Kallistatin’s anti-aging effect is mainly attributed to 
suppression of oxidative stress by preventing miR-34a-mediated inhibition of antioxidant 
gene expression. This study established an essential role of kallistatin’s active site in the 
regulation of miR-34a, SIRT1, and eNOS synthesis by interaction with a tyrosine kinase. 
As kallistatin is an endogenous protein, minimal side effects are expected with kallistatin 
treatment. Therefore, this study opens a new prospective in kallistatin-based therapeutic 















TO DETERMINE THE ROLE OF ENDOGENOUS KALLISTATIN IN 





This study is aimed to further investigate the role and mechanism of endogenous 
kallistatin in endothelial senescence, vascular and organ injury. Kallistatin treatment 
inhibited H2O2-induced senescence in human endothelial cells, as indicated by reduced 
senescence-associated-β-galactosidase activity, p16INK4a and plasminogen activator 
inhibitor-1 expression, and elevated telomerase activity. Kallistatin blocked H2O2-induced 
superoxide formation, NADPH oxidase levels, and VCAM-1, ICAM-1, IL-6, and miR-34a 
synthesis. Kallistatin reversed H2O2-mediated inhibition of eNOS, SIRT1, catalase and 
superoxide dismutase (SOD)-2 expression, and directly stimulated these genes. 
Moreover, kallistatin’s anti-senescence and antioxidant effects were attributed to SIRT1-
mediated eNOS pathway. Kallistatin, via interaction with tyrosine kinase, upregulated 
Let-7g, whereas Let-7g inhibitor abolished kallistatin’s effects on miR-34a and 
SIRT1/eNOS synthesis, leading to inhibition of senescence, oxidative stress and 
inflammation. Furthermore, lung endothelial cells isolated from endothelium-specific 
kallistatin knockout mice displayed marked reduction of mouse kallistatin expression. 
Kallistatin deficiency in mouse endothelial cells exacerbated senescence, oxidative 
stress and inflammation compared to wild-type mouse endothelial cells, and H2O2 
treatment further magnified these effects. Kallistatin deficiency caused marked reduction 
of Let-7g, SIRT1, eNOS, catalase and SOD-1 mRNA levels, and elevated miR-34a 
synthesis in mouse endothelial cells. Moreover, systemic depletion of kallistatin resulted 
in worsened aortic oxidative stress and renal injury and fibrosis in general kallistatin 
knockout mice with diabetes. These findings indicate that endogenous kallistatin protects 
against endothelial senescence, vascular and organ injury and kallistatin treatment 
reduces endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS 




Endothelial senescence contributes to the onset and development of vascular 
injury and age-associated vascular diseases, such as atherosclerosis, diabetes, and 
coronary artery diseases (Minamino et al., 2004, Minamino & Komuro, 2007). Vascular 
senescence gives rise to the alteration of morphological features and functional 
physiology in blood vessels (Cavallaro et al., 2000). The key features of senescent cells 
are: permanent growth arrest state, flattened morphology, elevation of SA-β-gal activity, 
cell cycle inhibitor p16INK4a expression, and endothelial dysfunction marker plasminogen 
activator inhibitor-1 (PAI-1) expression. Moreover, cellular senescence is characterized 
by shortened telomere length or reduced telomerase activity (Hornsby, 2007). Oxidative 
stress and inflammation have been implicated in the aging process and adversely affect 
endothelial availability and function (Freund et al., 2010, Bhayadia et al., 2016). 
Oxidative stress compromises telomere integrity and nitric oxide (NO) bioavailability to 
accelerate cellular senescence in endothelial cells (Kurz et al., 2004). Vascular 
senescence is also associated with enhanced expression of the inflammatory molecules, 
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 
(ICAM-1), which leads to augmented adhesion of monocytes into vascular wall, 
facilitating the ignition and progression of aging-associated vascular diseases (Gorgoulis 
et al., 2005, Powter et al., 2015). Therefore, inhibition of oxidative stress and 
inflammation is of great significance for controlling endothelial senescence. 
 
miRNAs are essential regulators for a plethora of cellular processes. A highly 
evolutionarily conserved miRNA Let-7g has been reported to inhibit oxLDL-induced 
apoptosis of endothelial cells and alleviate atherosclerosis in mice (Zhang et al., 2013, 
Liu et al., 2017). Let-7g also has the ability to improve multiple endothelial functions by 
stimulating SIRT1 signaling (Liao et al., 2014). Furthermore, miR-34a, a well-recognized 
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tumor suppressor and a senescent inducer, triggers endothelial senescence by directly 
suppressing the target gene SIRT1 (Ito et al., 2010). SIRT1, an NAD+-dependent 
deacetylase and anti-aging molecule, is decreased in vascular tissue undergoing 
senescence. Evidence has indicated a positive feedback regulation between SIRT1 and 
eNOS. SIRT1 promotes the expression of eNOS and activates eNOS by its deacetylase 
activity, while eNOS through NO production stimulates SIRT1 expression 
(Mattagajasingh et al., 2007, Potente & Dimmeler, 2008, Xia et al., 2013). NO produced 
from eNOS has a wide range of biological properties to maintain vascular homeostasis, 
including vascular dilation, and inhibition of oxidative stress and inflammation. Therefore, 
Let-7g, miR-34a, and antioxidant genes SIRT1 and eNOS are key signaling molecules 
for regulating endothelial senescence.   
 
Recently plasma kallistatin levels have been shown to be positively associated 
with leukocyte telomere length in young African Americans, implicating the involvement 
of kallistatin in anti-aging process (Zhu et al., 2016). Moreover, kallistatin depletion by 
neutralizing antibody injection worsens cardiovascular and renal injury, oxidative stress 
and inflammation in hypertensive rats (Liu et al., 2011), indicating endogenous kallistatin 
may have a role in vascular and organ injury. H2O2 is widely used to achieve oxidative 
stress-induced premature senescence in endothelial cells and fibroblasts (Chen J. H. et 
al., 2007, Liu D. H. et al., 2012). According to previous findings, the dose of H2O2 (100 
µM) represents subcytotoxic conditions to induce senescence (Frippiat et al., 2001, Li R. 
L. et al., 2016). In this study, we further investigated the role and mechanism of 
kallistatin in oxidative stress-induced endothelial senescence by 1) exogenous kallistatin 
treatment in human endothelial cells, and 2) endogenous kallistatin deficiency in mouse 
lung endothelial cells isolated from endothelium-specific kallistatin-deficient (KSendo-/-) 
mice. General kallistatin knockout (KS-/-) mice were also generated and subjected to 
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streptozotocin (STZ) challenge, which is a chemical agent to induce diabetes by 
damaging islet β-cells. We further determined the role of endogenous kallistatin in 






Material and Methods 
Human Endothelial Cell Culture and Treatments 
Human umbilical vein endothelial cells (HUVECs) were cultured as previously 
described in Chapter II. HUVECs at 80% confluency were pre-treated with kallistatin (1 
µM) followed by hydrogen peroxide (H2O2, 100 µM; Fisher Scientific) challenge for 3 
days in serum-free EBM-2 medium; senescent markers and oxidative stress indicators 
were evaluated. To measure gene expression, HUVECs were pre-incubated with 
kallistatin (1 µM) followed by H2O2 (100 µM) treated for 24 h. To determine the causal 
relationship of SIRT1 and eNOS, HUVECs were pre-treated with SIRT1 inhibitor 
nicotinamide (NAM, 5 mM; Sigma) or NOS inhibitor Nω-nitro-L-arginine methyl ester 
hydrochloride (L-NAME, 100 µM; Sigma) for 30 min, followed by kallistatin (1 µM) and 
H2O2 (100 µM) treatment for 24 h. Similarly, cultured primary mouse lung endothelial 
cells at 80% confluency were treated with or without H2O2 (100 µM) for 3 days to 
evaluate senescent markers and oxidative stress indicators, and for 24 h to measure 
gene expression 
 
SA-β-gal Staining  
Cellular senescence of HUVECs or mouse lung endothelial cells in 12-well plates 
was determined with SA-β-gal staining kit (Cell Signaling).  
 
Telomerase Activity Assay  
Telomerase activity was measured using TRAPEZE RT telomerase detection kit 
(EMD Millipore).  
 
NADPH Oxidase Activity Assay  
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The enzymatic activity of NADPH oxidase was assessed by a luminescence 
assay in the presence of lucigenin (250 µM; Sigma) and NADPH (100 µM; Sigma).  
 
Detection of Superoxide Formation  
HUVECs superoxide generation was detected using the fluorescent probe 2’, 7’-
dichlorodihydrofluorescein diacetate (DCFH-DA; 10 μM, Sigma). Superoxide levels in 
mouse lung endothelial cells and mouse thoracic aortas were determined by fluorescent 
probe dihydroethidium (DHE; 3 µM, Sigma).  
 
miRNA Transfection 
HUVECs were grown in antibiotic-free EBM-2 on plates for 24 h, and then 
transfected with Let-7g inhibitor (10 pM, antisense RNA Let-7g), miR-34a mimic or 
control miRNA (10 pM; Life Technologies) with Lipofectamine RNAiMAX reagent (Life 
Technologies) according to the manufacturer's protocol.  
 
Quantitation of mRNA by qRT-PCR 
RNA extraction, reverse transcription and Real-time PCR were performed as 
previously described in Chapter II method section. The following primers were used: 
human 18S, p16INK4a, eNOS, SIRT1, catalase, PAI-1, NADPH oxidase 4 and miR-34a; 
mouse GAPDH, eNOS, SIRT1, catalase and miR-34a as described in Chaper III. 
Superoxide dismutase (SOD)-2 (Hs00167309_ml), ICAM-1 (Hs00277001_ml), 
interleukin (IL)-6 (Hs00174131_ml), VCAM-1 (Hs00365486_ml), Let-7g (002282), mouse 
SOD-1 (Mm01344233_gl), mouse VCAM1 (Mm01320970_ml), mouse IL-6 
(Mm00446190_ml), mouse ICAM-1 (Mm00516024_gl), mouse kallistatin 
(Mm00434669_ml), mouse PAI-1 (Mm00435858_ml), mouse p16INK4a 
 
 75 
(Mm00494449_ml). Data were analyzed with 2−ΔΔCt value calculation using control genes 
for normalization.  
 
Western Blot  
Lysed cell sample were lysed, separated and immunobloted as previously 
described in Chapter II. Primary antibodies were anti-SIRT1, anti-eNOS, anti-mouse 
kallistatin, anti-β-actin, anti-Tie2, anti-fibronectin, anti-α-SMA and anti-α-tubulin (Cell 
Signaling).  
 
Generation of Endothelium-Specific Kallistatin Knockout Mice  
Heterozygous kallistatin floxing mice in C57/BL6 strain (male and female, KSfl/+) 
were obtained from Biocytogen, LLC (Worcester), and male wild-type C57/BL6 mice (7-8 
weeks of age) were purchased from Harlan (Indianapolis). These mice were housed in a 
germ-free environment. All procedures complied with the standard for care and use of 
animal subjects as stated in the Guide for the Care and Use of Laboratory Animals 
(Institute of Laboratory Resources, National Academy of Sciences). KSfl/+ mice were 
inbred to produce homozygous floxed kallistatin mice (KSfl/fl). To generate endothelium-
specific heterozygous kallistatin knockout mice (Tie2Cre+KSfl/+), female KSfl/fl mice were 
crossed with male Tie2-Cre mice (The Jackson Laboratories). Tie2Cre+KSfl/+ mice were 
then crossed with KSfl/fl mice to generate endothelium-specific kallistatin knockout 
(KSendo-/-) mice. The expression of mouse kallistatin null allele in endothelium of KSendo-/- 
mice was determined by PCR with a pair of custom primers: 5’-TCA AGT CCC TCA TGT 
GCG TTG GTA G-3’, and 5’-ATG TCA ATC ACA ATG CCC TCT GCC T-3’. The 
amplification conditions are 95°C for 5 min and 35 cycles of 95°C for 30 s, 63°C for 30 s, 
and 72°C for 1 min, followed by a 10-min incubation at 72°C at the end of the run. 
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Amplification products were resolved on a 3% agarose gel. Mouse kallistatin deficiency 
in isolated mouse lung endothelial cells was verified by qRT-PCR and western blot. 
 
Isolation and Identification of Mouse Lung Endothelial Cells 
Mouse lung endothelial cells were isolated from 8-week-old KSendo-/- and WT mice 
as described (Alphonse et al., 2015). Mice were euthanized by CO2 inhalation followed 
by cervical dislocation. The lungs were digested with 0.1% collagenase in PBS for 45 
min. The cell suspension was isolated by magnetic immunoselection with CD31-
conjugated magnetic beads (Miltenyi Biotec) using the magnetic-activated cell sorting 
system (MACS, Miltenyi Biotec). Purified mouse lung endothelial cells were cultured on 
gelatin-coated tissue culture dishes with EBM-2 medium with 10% FBS and 1% 
antibiotics until they became confluent.  Newly grown colonies were digested, incubated 
with CD31 magnetic beads and selected through MACS again. After the second 
selection, mouse lung endothelial cells were seeded in a T75 flask provided with 
complete EBM-2 medium to grow robustly. Mouse endothelial cells were characterized 
with endothelial marker CD31 by PCR and immunostaining. For immunostaining, mouse 
endothelial cells were fixed with 4% paraformaldehyde, incubated with blocking buffer, 
and followed with rat anti-mouse CD31 antibody (Santa Cruz Biotechnology) overnight at 
4°C. After washing with PBS, cells were incubated with anti-rat FITC secondary antibody 
(Sigma) for 1 h at room temperature, washed with PBS, and counterstained with 
Hoechst 33342 (1 µg/ml; Sigma).  
 
Generation and Identification of General Kallistatin Knockout Mice 
To generate heterozygous kallistatin knockout mice (CAGCre+KSfl/+), female 
KSfl/fl mice were crossed with male CAG-Cre mice (The Jackson Laboratories). 
CAGCre+KSfl/+ mice were then crossed with KSfl/fl mice to produce CAGCre+KSfl/fl mice. 
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Mice at the age of 4-5 week-old were subcutaneously injected with tamoxifen (75mg/kg, 
dissolved in corn oil) for 5 days to induce Cre recombinase activity. Genotyping were 
performed after one week of tamoxifen induction using 0.5 cm tail biopsy. Serpina3c-
A1Loxp-F 5’-CTG CTC ATG ATG TAG GAG ATC TTA GC-3’, Serpina3c-A1Loxp-R 5’-
TCC AGT CAT GGT TTG GAT AGT GG-3’; Cre-F: 5’-GCG GTC TGG CAG TAA AAA 
CTA TC-3’, Cre-R: 5’-GTG AAA CAG CAT TGC TGT CAC TT-3’. The amplification 




Male KS-/- mice and WT littermates (12 weeks of age) were subjected to 6-day 
continuous intraperitoneal injections of STZ (60 mg/kg; Sigma). Sodium citrate buffer 
(0.1 M, pH 4.5) was injected in control animals. Mice with blood glucose > 250 mg/dL 
were considered diabetic. A total of 24 mice were randomly assigned to three groups: 
WT group (n = 6), KS-/- group, WT+STZ group (n = 6), and KS-/- +STZ group (n = 6). Two 
months after blood glucose stabilization, thoracic aortas and kidney samples were 
collected for histological analysis or western blot analysis. 
 
Morphological Investigations 
5 µm-thick renal sections and 8 µm-thick aortic sections were obtained from each 
sample. Renal sections were stained with Sirius red to determine the extent of fibrosis. 
Artery sections were stained with dihydroethidium (DHE; Signma) at 37°C for superoxide 
determination. Primary antibodies for VE-cadherin, CD31 and α-SMA were used to 
detect in HUVECs with fluorescence microscopy. Briefly, cells were fixed with 4% 
paraformaldehyde and permeabilized with 0.2% Triton X-100, and blocked with 3% BSA 
in PBS for 1 h at room temperature, followed by incubation with primary antibody 
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overnight at 4°C. After incubation, cells were rinsed three times with PBS and incubated 
with fluorochrome-conjugated secondary antibody for 2 h at room temperature in the 
dark. Cells were then washed with PBS and counter stained with Hoechst 33342 (5 
µg/ml; Cell Signaling Technology) for 5 min. Plates were then observed under a 
fluorescence microscope. 
 
Assays for Plasma Creatinine and Blood Urea Nitrogen (BUN) Levels 
Plasma was collected from each sample. Protein levels in plasma were 
measured by Pierce BCA protein assay kit (Thermo Fisher Scientific). Plasma creatinine 
or BUN levels were determined using Quantichrom creatinine assay kit (DITC500) or 
Quantichrom urea assay kit (DIUR-500)  (BioAssay Systems). 
 
Statistical Analysis  
Data are presented as mean ± S.E.M. Statistical analyses were performed with 
GraphPad Prism 7 (GraphPad Software). ANOVA and Student’s t-test analysis were 
used to assess differences between data means as appropriate. A value of P < 0.05 was 
considered statistically significant. 




Kallistatin Attenuates H2O2-Induced Cellular Senescence in Human Endothelial 
Cells 
Representative images showed that H2O2 treatment induced pronounced cellular 
senescence in HUVECs, characterized by increased senescent marker SA-β-gal activity 
compared with the control group, while purified recombinant human kallistatin 
pretreatment reversed the effect (Figure 4-1 A). Quantitative analysis of positive SA-β-
gal staining cells confirmed the results (Figure 4-1 B). Senescent markers p16INK4A, PAI-
1 and telomerase were also evaluated. Kallistatin blocked H2O2-induced p16INK4A and 
PAI-1 expression, and prevented H2O2-mediated inhibition of telomerase activity (Figure 
4-1 C-E). Therefore, kallistatin is capable of blocking oxidative stress-induced 
endothelial senescence. 
 
Kallistatin Inhibits H2O2-Induced Oxidative Stress and Inflammation  
Representative images showed that kallistatin attenuated H2O2-induced 
superoxide formation in human endothelial cells, which was verified by quantitative 
analysis (Figure 4-2 A&B). Similarly, kallistatin antagonized H2O2-induced NADPH 
oxidase activity and NADPH oxidase 4 mRNA levels (Figure 4-2 C&D). Moreover, 
kallistatin inhibited H2O2-mediated expression of the pro-inflammatory genes VCAM-1, 
ICAM-1 and IL-6 (Figure 4-2 E-G). Kallistatin alone inhibited miR-34a, and prevented 
H2O2-induced miR-34a synthesis (Figure 4-2 H). These results indicate that kallistatin 
inhibits H2O2-induced oxidative stress and inflammation in endothelial cells.  
 
Kallistatin Inhibits Endothelial Senescence and Oxidative Stress through SIRT1-
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Figure 4-1. Kallistatin (KS) alleviates H2O2-induced endothelial senescence in human 
endothelial cells. (A) Representative images of SA-β-gal staining. (B) Quantification 
analysis of positive SA-β-gal staining cells. (C) QPC analysis of p16INK4a. (D) QPCR 
analysis of PAI-1 mRNA levels. (E) Telomerase activity determined by QPCR (C-D). 
















                              








   
 
 












Figure 4-2 A-D. Kallistatin (KS) suppresses H2O2-induced oxidative stress in human 
endothelial cells. (A) Representative images of superoxide formation determined by 
fluorescence dye oxidized DCF. (B) Quantitative analysis of fluorescent counts. (C) 
QPCR analysis of NADPH oxidase 4 mRNA levels. (D) NADPH oxidase activity 
determined by lucigenin chemiluminescence assay. n=3. *P < 0.05 vs. control, #P < 0.05 
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Figure 4-2 E-H. Kallistatin (KS) suppresses H2O2-induced inflammation and miR-34a 
synthesis in human endothelial cells. QPCR analysis of (A) VCAM-1, (B) ICAM-1, (C) IL-
6 and (D) miR-34a RNA levels. n=3. *P<0.05 vs. control, #P<0.05 vs. H2O2 group. 
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In order to determine whether the kallistatin-mediated protection against 
endothelial senescence is associated with antioxidant gene regulation, the effects of 
kallistatin on the regulation of SIRT1, eNOS, catalase and SOD-2 were determined. 
Kallistatin treatment not only markedly enhanced SIRT1, eNOS, catalase and SOD-2 
expression, but also prevented H2O2-mediated inhibition of these antioxidant genes 
(Figure 4-3 A-D). Moreover, NAM, a potent inhibitor of SIRT1 activity, blocked kallistatin-
stimulated eNOS expression, whereas L-NAME, an NOS inhibitor, had no effect on 
kallistatin-stimulated SIRT1 expression (Figure 4-3 E&F), indicating that kallistatin via 
SIRT1 elevation stimulates eNOS. Furthermore, NAM abolished kallistatin’s antioxidant 
activity and anti-senescent action, as evidenced by reversing kallistatin’s inhibition of 
SA-β-gal activity and NADPH oxidase activity in HUVECs (Figure 4-3 G&H). These 
results indicate that the SIRT1-mediated eNOS pathway plays a crucial role in 
kallistatin’s inhibition of endothelial senescence and oxidative stress.  
 
Kallistatin by Let-7g Upregulation Blocks miR-34a-Mediated Inhibition of SIRT1-
eNOS Pathway, and Reduces Endothelial Senescence, Oxidative Stress and 
Inflammation  
To illustrate whether kallistatin-mediated inhibition of endothelial senescence was 
associated with upregulation of Let-7g, the effect of kallistatin on Let-7g expression was 
determined. Kallistatin treatment significantly increased Let-7g synthesis, whereas 
genistein, a tyrosine kinase inhibitor, blocked kallistatin’s effect (Figure 4-4 A), 
implicating that kallistatin interacts with a cell surface tyrosine kinase to stimulate Let-7g 
synthesis. Let-7g inhibitor (Let-7g anti-sense RNA) blocked kallistatin’s inhibition of miR-
34a synthesis (Figure 4-4 B), indicating that kallistatin regulates Let-7g-mediated miR-
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Figure 4-3 A-D. Kallistatin (KS) stimulates antioxidant gene expression and prevents 
H2O2-mediated inhibition of these genes in human endothelial cells. QPCR analysis of 
(A) SIRT1, (B) eNOS, (C) catalase and (D) SOD-2 mRNA levels. n=3. *P < 0.05 vs. 
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Figure 4-3 E-H. Kallistatin (KS) inhibits H2O2-induced senescence and oxidative stress 
through SIRT1-eNOS pathway in human endothelial cells. QPCR analysis of (E) eNOS 
and (F) SIRT1 mRNA levels. (G) Quantification analysis of SA-β-gal positive staining 
cells. (H) NADPH oxidase activity determined by lucigenin chemiluminescence. n=3. *P 
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Figure 4-4 A-E. Kallistatin (KS) through Let-7g to inhibit miR-34a and elevate SIRT1 and 
eNOS synthesis in human endothelial cells. QPCR analysis of (A) Let-7g, (B) miR-34a, 
(C) Let-7g, (D) SIRT1 and (E) eNOS mRNA levels. GEN: genistein, a tyrosine kinase 





expression (Figure 4-4 C), thus kallistatin’s effect on Let-7g upregulation is independent 
of miR-34a. Moreover, Let-7g inhibitor abolished kallistatin-induced SIRT1 and eNOS 
mRNA levels, and blocked kallistatin-mediated elevation of SIRT1 and eNOS levels by 
western blot (Figure 4-4 D-F), indicating an essential role of Let-7g in kallistatin’s 
induction of antioxidant genes. Furthermore, Let-7g inhibitor abolished kallistatin’s 
inhibitory effect on H2O2-induced senescence, characterized by elevated p16INK4a and 
PAI-1 mRNA levels in endothelial cells (Figure 4-4 G&H). Likewise, Let-7g inhibitor 
blocked kallistatin’s effect on H2O2-induced NADPH oxidase activity and VCAM-1 
expression (Figure 4-4 I&J). These combined findings indicate that kallistatin, by 
interacting with a tyrosine kinase, upregulates Let-7g, thus inhibiting miR-34a-SIRT1-
eNOS pathway. Therefore, Let-7g plays a crucial role in mediating kallistatin’s inhibitory 
effects on endothelial senescence.  
 
Identification of Kallistatin Deficiency in Mouse Lung Endothelial Cells 
We generated endothelium-specific kallistatin knockout (KSendo-/-) mice by 
crossing KSfl/fl mice with Tie2Cre+KSfl/+ mice. Lung endothelial cells were isolated from 
WT mice and KSendo-/- mice. Cultured primary mouse lung endothelial cells were 
identified by CD31 expression and immunostaining (Figure 4-5 A&B). In lysed mouse 
endothelial cell DNA samples, kallistatin null allele (del) was detected only in KSendo-/- 
mice, but not in WT mice (Figure 4-5 C), indicating that endogenous kallistatin is ablated 
in mouse endothelial cells. Moreover, the protein and mRNA levels of mouse kallistatin 
were markedly diminished in endothelial cells from KSendo-/- mice, compared with 
endothelial cells from WT mice (Figure 4-5 D&E).  These results confirm that mouse 
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Figure 4-4 F-J. Kallistatin through Let-7g induction stimulates SIRT1 and eNOS, and 
inhibits endothelial senescence, oxidative stress and inflammation. (F) Representative 
western blot of SIRT1 and eNOS and quantification. QPCR of (G) p16INK4a and (H) PAI-
1. (I) Chemiluminescence analysis of NADPH oxidase activity. (J) QPCR analysis of 
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Figure 4-5. Identification of kallistatin (KS) deficiency in isolated mouse lung endothelial 
cells. (A) Representative images of immunostaining of endothelial marker CD31 
expression in mouse lung endothelial cells. (B) CD31 expression determined by PCR. 
(C) Identification of mouse kallistatin depletion (del) by target null gene DNA 
electrophoresis. (D) Representative immunoblots of mouse KS protein. (E) QPCR 




Kallistatin Deficiency Aggravates Oxidative Stress-Induced Senescence, Oxidative 
Stress and Inflammation in Mouse Endothelial Cells 
Cultured primary mouse lung endothelial cells with or without H2O2 treatment 
were used to determine the effect of kallistatin deficiency on endothelial senescence, 
oxidative stress and inflammation. In the non-H2O2-treated groups, kallistatin-deficient 
endothelial cells displayed increased SA-β-gal activity, p16INK4a and PAI-1 expression, 
compared to WT mouse endothelial cells (Figure 4-6 A-C). Mouse kallistatin deficiency 
in H2O2–treated endothelial cells further enhanced the levels of senescence makers, 
compared to H2O2–treated WT mouse endothelial cells (Figure 4-6 A-C). Moreover, 
cellular superoxide formation and NADPH oxidase activity were increased upon H2O2 
treatment, and kallistatin deficiency further enhanced superoxide formation and NADPH 
oxidase activity (Figure 4-6 D&E). Likewise, kallistatin deficiency increased H2O2-
induced VCAM-1, ICAM-1 and IL-6 mRNA levels in kallistatin-deficient endothelial cells 
(Figure 4-6 F-H). Therefore, kallistatin deficiency in mouse endothelial cells exacerbates 
endothelial senescence, oxidative stress and inflammation. These findings implicate a 
protective role of endogenous kallistatin in stress-induced endothelial senescence.  
 
Kallistatin Deficiency Reduces Let-7g and Antioxidant Gene Expression and 
Increases miR-34a Synthesis in Mouse Endothelial Cells 
Kallistatin deficiency in KSendo-/- mouse endothelial cells caused a significant 
reduction of Let-7g, SIRT1, eNOS, catalase and SOD-1 expression compared with WT 
mouse cells (Figure 4-7 A-E). Moreover, H2O2 treatment reduced the expression of Let-
7g and antioxidant genes in endothelial cells from WT mice, and kallistatin deficiency 
further reduced the expression of these genes (Figure 4-7 A-E). Conversely, kallistatin 
deficiency increased miR-34a synthesis in mouse lung endothelial cells, compared with 
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Figure 4-6 A-E. Kallistatin (KS) deficiency in mouse lung endothelial cells increases 
senescence and oxidative stress. (A) Quantitative analysis of SA-β-gal activity. QPCR 
analysis of (B) p16INK4a and (C) PAI-1 mRNA levels. (D) Superoxide formation 
determined by oxidized DCF fluorescent probe. (E) NADPH oxidative activity determined 










                                 F 
																																							 					
	




Figure 4-6 F-H. Kallistatin (KS) deficiency in mouse lung endothelial cells exacerbates 
inflammatory gene expression. QPCR analysis of (F) VCAM-1, (G) ICAM-1 and (H) IL-6 
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Figure 4-7. Kallistatin (KS) deficiency inhibits the synthesis of Let-7g and antioxidant 
genes and elevates miR-34a in mouse lung endothelial cells. QPCR analysis of (A) Let-
7g, (B) SIRT1, (C) eNOS, (D) catalase, (E) SOD1 and (F) miR-34a. n=3. *P < 0.05 vs. 







indicate that endothelial senescence in kallistatin-deficient mouse endothelial cells is 
attributed to downregulation of Let-7g and antioxidant genes, and elevation of miR-34a.  
 
Systemic Depletion of Kallistatin Aggravates Aortic Oxidative Stress and Renal 
Fibrosis in Diabetic Mice 
We generated general kallistatin knockout (KS-/-) mice. Kallistatin null allele (del) 
was only detected in KS-/- mice (Figure 4-8 A). Kallistatin depletion was also identified by 
the dramatic reduction of protein levels of mouse kallistatin in the kidney of KS-/- mice 
(Figure 4-8 B). Kallistatin ablation exacerbated STZ-induced superoxide formation and 
NADPH oxidase activity in aortas of diabetic mice, compared with aortas of diabetic WT 
mice (Figure 4-8 C&D). Compared with STZ WT mice, kallistatin ablation also caused 
the rupture of neointima and thickening of the smooth muscle layer of mouse aorta 
(Figure 4-8 C), indicating that kallistatin deficiency exacerbates vascular injury. 
Moreover, kallistatin depletion decreased SIRT1 and eNOS expression in aorta, STZ 
treatment further downregulated these protein levels (Figure 4-8 E). Regarding diabetes-
associated renal injury, we found that kallistatin knockout aggravated renal dysfunction 
as increased plasma creatinine and BUN levels (Figure 4-8 F&G). Sirius red staining 
result showed that kallistatin depletion markedly increased STZ-induced renal interstitial 
fibrosis compared with the kidney of WT diabetic mice (Figure 4-8 H&I). To determine 
whether EndMT occurs in diabetes-induced renal fibrosis, we evaluated the expression 
of endothelial marker Tie2, and mesenchymal markers such as α-SMA and fibronectin 
(Figure 4-8 J). STZ treatment decreased Tie2, but elevated α-SMA and fibronectin 
protein levels; and kallistatin deficiency further augmented STZ-mediated effects on 
these markers, implicating that more fibrosis emerges in the kidney of diabetic KS-/- 
mice. Collectively, endogenous kallistatin is essential for protection against vascular 
injury and renal fibrosis in diabetic mice. 
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Figure 4-8 A-E. Kallistatin (KS) depletion exacerbates aortic oxidative stress in STZ-
induced diabetic mice. (A) Genotyping PCR. (B) Representative western blot of mouse 
kallistatin in kidney samples and quantification analysis. (C) Representative images of 
aortic superoxide formation labeled by red fluorescence dye DHE. (D) Aortic NADPH 
oxidase activity chemiluminescence. (E) Representative western blots of aortic SIRT1 
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Figure 4-8 F-J. Kallistatin (KS) depletion exacerbates renal injury and fibrosis in STZ-
induced diabetic mice. (F) Plasma creatinine levels. (G) Plasma BUN levels. (H) 
Representative images of sirius red staining in kidney sections. (I) Quantification of 
collagen fraction. (J) Representative western blots of endothelial marker Tie2, and 
mesenchymal markers fibronection and α-SMA. n=4. *P < 0.05 vs. WT group; #P < 0.05 











Figure 4-9. Signaling pathway by which kallistatin inhibits endothelial senescence, 
oxidative stress and inflammation. Kallistatin through tyrosine kinase stimulates Let-7g 
synthesis, inhibits miR-34 and upregulates SIRT1-mediated-eNOS pathway, thereby 
elevating catalase, SOD-1/2 and NO levels, leading to blockade of H2O2-modulated ROS 
formation, p16INK4a, PAI-1, VCAM-1, ICAM-1, and IL-6 expression, and telomerase 
activity in endothelial cells. Genistein, tyrosine kinase inhibitor; NAM, SIRT1 inhibitor; L-




This study demonstrates that endogenous kallistatin plays a protective role in 
endothelial senescence, aorta oxidative stress and organ injury, and kallistatin through a 
novel mechanism inhibits cellular senescence, oxidative stress and inflammation. 
Kallistatin antagonized oxidative stress-induced senescence, as indicated by inhibiting 
p16INK4a and PAI-1 levels and increasing telomerase activity in human endothelial cells. 
Moreover, kallistatin, via tyrosine kinase, upregulated Let-7g, thus preventing miR-34a-
mediated inhibition of the SIRT1-eNOS pathway. Activation of SIRT1-eNOS signaling 
resulted in increased catalase, SOD-1/2 and NO levels, and decreased ROS formation, 
VCAM-1, ICAM-1 and IL-6 expression. The signaling mechanism by which kallistatin 
inhibits endothelial senescence, oxidative stress and inflammation is shown in Figure 4-
9. To confirm the pivotal role of endogenous kallistatin in protection against endothelial 
senescence, we generated endothelial cell-specific kallistatin knockout (KSendo-/-) mice 
and general kallistatin knockout mice (KS-/- mice). The protective actions of endogenous 
kallistatin in vascular senescence were validated by exacerbated senescence, oxidative 
stress and inflammation in mouse lung endothelial cells isolated from KSendo-/- mice. 
Importantly, kallistatin is essential for protection of vascular and organ injury as systemic 
depletion of kallistatin aggravated vascular oxidative stress and renal interstitial fibrosis 
in diabetic mice. The current study indicates an important role of kallistatin in vascular 
injury and age-related vascular diseases. 
 
Oxidative stress and inflammation are hallmarks of endothelial senescence 
(Erusalimsky, 2009, Salminen et al., 2012). Kallistatin administration has been shown to 
attenuate vascular injury and organ damage and aging, in conjunction with reduced 
oxidative stress and inflammation in animal models with hypertension, arthritis, diabetes 
and sepsis (Shen et al., 2008, Shen et al., 2010, Yin et al., 2010, Li et al., 2014, Lin et 
 
 99 
al., 2015, Yiu et al., 2016). In this study, we showed that kallistatin inhibited H2O2-
induced oxidative stress and pro-inflammatory gene expression, including VCAM-1, 
ICAM-1 and IL-6, in human endothelial cells. Moreover, kallistatin stimulated antioxidant 
gene expression, including SIRT1, eNOS, catalase and SOD-2. NO production by eNOS 
inhibits superoxide formation and inflammation. Catalase, one of SIRT1’s downstream 
antioxidant enzymes, is decreased in H2O2-induced premature senescence. Human 
SOD-2 and mouse SOD-1 are antioxidant enzymes and play an important role in the 
prevention of endothelial senescence and inflammation (Velarde et al., 2012, Zhang et 
al., 2017).  Previous reports indicated a reciprocal positive feedback regulation between 
SIRT1 and eNOS. SIRT1 has been shown to induce eNOS expression and activity, and 
eNOS through NO formation upregulates SIRT1 and maintains vascular homeostasis. 
Kallistatin was shown to increase SIRT1 and eNOS synthesis in human endothelial cells 
and EPCs (Guo et al., 2015, 2017). Moreover, kallistatin treatment increased eNOS 
activity and NO formation in human endothelial cells (Shen et al., 2010). The present 
study shows that kallistatin stimulates SIRT1-mediated eNOS pathway, as kallistatin-
induced eNOS expression was blocked by SIRT1 inhibitor NAM, but kallistatin-mediated 
SIRT1 expression was not affected by NOS inhibitor L-NAME. Collectively, kallistatin 
through stimulating SIRT1-mediated eNOS pathway protects against senescence, 
oxidative stress and inflammation.  
 
Let-7g was recently recognized as an anti-aging miRNA to improve endothelial 
functions (Liao et al., 2014). Let-7g negatively regulated apoptosis, senescence and 
inflammation in endothelial cells (Zhang et al., 2013; Liao et al., 2014; Liu et al. 2017). 
Upregulation of SIRT1 levels was involved in Let-7g-mediated inhibition of endothelial 
senescence. In this study, we showed that kallistatin increased Let-7g synthesis, and 
kallistatin, via Let-7g induction, stimulated SIRT1 and eNOS, leading to inhibition of 
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endothelial senescence, oxidative stress and inflammation in endothelial cells. 
Importantly, kallistatin harbors two structural elements, an active site and a heparin-
binding domain. Kallistatin’s active site is essential for eNOS and SIRT1 expression 
through interacting with a tyrosine kinase in EPCs and endothelial cells (Guo et al. 2015, 
2017). It is likely that kallistatin via the active site interacts with tyrosine kinase to 
stimulate Let-7g synthesis. Moreover, miR-34a-SIRT1 axis has been regarded to be one 
of critical pathways to regulate endothelial senescence (Ito et al. 2010). Our previous 
study showed that kallistatin reduced EPC senescence and aorta aging by inhibiting the 
synthesis of miR-34a, a pro-senescent miRNA. Consistently, the current study indicates 
that kallistatin treatment prevented H2O2-induced miR-34a synthesis in endothelial cells. 
Importantly, we found that Let-7g is the upstream regulator of miR-34a in response to 
kallistatin treatment. These results indicate that kallistatin protects against endothelial 
senescence by upregulating Let-7g to inhibit miR-34a-SIRT1-eNOS pathway. 
 
 To further investigate the role of endogenous kallistatin in vascular senescence, 
KSendo-/- mice were produced by loxp/Cre technology, and lung endothelial cells from 
KSendo-/- mice and WT littermates were isolated and cultured. Kallistatin deficiency in 
mouse endothelial cells accelerated replicative senescence and superoxide formation. 
Upon H2O2 treatment, kallistatin deficiency further aggravated stress-induced 
senescence, oxidative stress and inflammation, indicating a protective role of 
endogenous kallistatin in maintaining endothelial viability and function. Furthermore, 
exacerbated senescence in KSendo-/- endothelial cells was associated with elevation of 
miR-34a, and reduction of Let-7g, SIRT1, eNOS, catalase and SOD-1. Thus, Let-7g-
mediated inhibition of miR-34a-SIRT1-eNOS pathway is suppressed when kallistatin is 
deficient. These combined findings support the notion that endogenous kallistatin acts as 
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a protective molecule in vascular injury and senescence by stimulating Let-7g, SIRT1 
and eNOS, and suppressing miR-34a synthesis.   
 
We generated general kallistatin knockout mice for the first time. There were no 
physiological changes except lighter body weight in male KS-/- mice. Kallistatin gene 
delivery has been shown to decrease aortic superoxide levels and glomerular 
endothelial loss, and reduce renal fibrosis in hypertensive rats (Shen et al., 2008; Shen 
et al., 2010). Conversely, kallistatin depletion by neutralizing kallistatin antibody injection 
exacerbated renal and cardiovascular oxidative stress, inflammation and organ injury in 
hypertensive rats (Liu et al., 2012). Here we used STZ-induced diabetic KS-/- mice to 
further confirm the role of kallistatin in vascular oxidative injury and renal fibrosis. In 
keeping with previous findings regarding kallistatin’s inhibition in EndMT, organ fibrosis 
and vascular injury (Shen et al., 2008; Shen et al., 2010; Guo et al., 2015), kallistatin 
depletion aggravated vascular oxidative stress and renal dysfunction and fibrosis. SIRT1 
and eNOS expression was significantly suppressed in aorta of KS-/- mice. EndMT 
markers were regulated towards pro-EndMT occurrence. Further studies need to 
perform to validate whether the interstitial fibrosis is originated from EndMT. These 
findings suggest that endogenous kallistatin plays a protective role in diabetes-induced 
vascular injury and renal fibrosis. 
 
 Overall, this study indicates that kallistatin inhibits cellular senescence, oxidative 
stress and inflammation by promoting Let-7g-mediated inhibition of miR-34a-SIRT1-
eNOS pathway in human endothelial cells. Moreover, endogenous kallistatin plays a 
protective role in endothelial senescence, vascular and organ injury. Therefore, 
kallistatin could potentially be used as a promising new therapeutic strategy for vascular 



















 The goal of this research project is to gain insights into the role and mechanism 
of kallistatin in vascular injury, senescence and aging, using cultured endothelial cells, 
EPCs, STZ-induced diabetic mice, kallistatin deficient mice (KSendo-/- and KS-/-) and C. 
elegans. Vascular-related diseases progress with advancing age, which is primarily 
attributed to pathophysiological changes in blood vessels (Strait & Lakatta, 2012). The 
structural remodeling is featured with neointima thickening, rarefaction of endothelial 
cells, increased oxidative stress and inflammation (Asahara et al., 1997, Lakatta, 2002, 
Foreman & Tang, 2003). Endothelial cells upon injury insults can undergo EndMT, 
senescence or inflammation (Erusalimsky, 2009, Agarwal et al., 2016). We first 
demonstrated the efficacy of kallistatin in preventing EndMT, a process mediating 
vascular injury, organ fibrosis and tumor progression. Moreover, kallistatin treatment 
reduced senescence and aging in cultured EPCs and endothelial cells, mouse aorta, 
and C. elegans. We found that the central mechanism for kallistatin in suppression of 
EndMT and vascular senescence is mediated by stimulating antioxidant gene 
expression. Conversely, endogenous kallistatin deficiency exacerbated endothelial 
senescence, oxidative stress and inflammation in mouse endothelial cells. In contrast to 
kallistatin’s efficacy in aortic injury and EndMT, systemic kallistatin depletion in KS-/- mice 
aggravated diabetes-induced vascular oxidative stress and renal fibrosis. These findings 
imply a crucial role of endogenous kallistatin in protection against vascular injury, 
senescence and aging. 
 
Our previous studies showed that kallistatin gene delivery inhibited renal fibrosis 
in hypertensive rats, cardiac fibrosis in rats with myocardial infarction, and tumor growth 
in mice with tumor xenografts (Miao et al., 2002, Gao et al., 2008, Shen et al., 2008). 
EndMT is a process mediating neo-intimal thickening by promoting endothelial cell 
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differentiation to matrix-producing fibroblasts (Arciniegas et al., 1992). Accumulating 
evidence indicates the involvement of EndMT in renal interstitial fibrosis, pulmonary 
fibrosis and cardiac fibrosis (Jimenez, 2013, Kong et al., 2014). Aberrant TGF-β-Akt 
signaling is primarily activated to drive fibrosis (Meadows et al., 2009). TGF-β promotes 
superoxide generation and matrix protein deposition and makes endothelial cells lose 
cell-cell junction and be invasive. miR-21, an oncogenic miRNA potentiates TGF-β 
responses by inhibiting phosphatase and tensin homolog (PTEN), an inhibitor of Akt 
phosphorylation (Kumarswamy et al., 2012). Our current study showed that kallistatin 
antagonized TGF-β-induced EndMT by blocking miR-21-Akt pathway and inhibiting 
oxidative stress. This study provided new insights that kallistatin via its active site 
stimulated eNOS and SIRT1 synthesis and via its heparin-binding domain blocked TGF-
β-induced miR-21-Akt pathway. These findings not only revealed the mechanism by 
which kallistatin inhibits EndMT but also provided supportive evidence that kallistatin 
through inhibiting EndMT protects against vascular injury, organ fibrosis and tumor 
progression.  
 
The supply of de novo endothelial cells by EPC pool renders EPCs essential for 
vascular repair (Rumpold et al., 2004). However, EPC senescence directly affects its 
normal rejuvenation capacity, leading to vascular injury (Heiss et al., 2005). Kallistatin 
has been found to increase circulating EPC number in hypertensive rats, and enhance 
EPC proliferation, migration, adhesion and tube formation in vitro by activation of PI3K-
Akt-eNOS pathway (Gao et al., 2014). Consistently, this study showed that kallistatin 
inhibited senescence-associated oxidative stress in EPCs by stimulating antioxidant 
genes, eNOS and SIRT1 synthesis. SIRT1 is a longevity gene, which is inversely 
regulated by miR-34a, a pro-senescent miRNA (Ito et al., 2010). Likewise, miR-21 is 
 
 105 
involved in accelerating cellular senescence in EPCs (Zhu et al., 2013). This is the first 
study to demonstrate that kallistatin inhibits EPC senescence associated with reduction 
of miR-34a, miR-21 and elevation of eNOS and SIRT1 levels. Inhibition of miR-21 and 
stimulation of antioxidant genes may extend kallistatin’s efficacy in EndMT to 
senescence. Notably, overexpression of miR-34a abolished kallistatin’s protective effect 
on senescence and SIRT1/eNOS stimulation, highlighting the important role of miR-34a 
in kallistatin-mediated anti-senescence in EPCs. Type 1 diabetes has been documented 
to be associated with aortic senescence (Ota et al., 2010). We used STZ to establish 
type 1 diabetes in mice. Our study supports the notion that kallistatin inhibits diabetes-
induced aortic senescence and oxidative stress by preventing miR-34a-SIRT1/eNOS 
pathway.  
 
Recent study reported that plasma kallistatin levels were positively associated 
with leukocyte telomere length in young African Americans (Zhu et al., 2016). Telomere 
length is a decisive factor for cellular lifespan, thus kallistatin may have a potential anti-
aging effect. Indeed, our study showed that kallistatin could suppress in situ superoxide 
formation and delay the aging process under heat or oxidative stress conditions in C. 
elegans. C. elegans possesses a short lifespan and conservative longevity gene 
expression. Two of the pronounced regulatory genes are miR-34 and sir-2.1 (SIRT1 
homolog). Kallistatin enhanced C. elegans survival under stress conditions in wild-type 
C. elegans but not in miR-34 mutant or sir-2.1 mutant worms, indicating a crucial role of 
miR-34 and SIRT1 in kallistatin–regulated longevity. This study demonstrated a role of 
kallistatin in delaying the aging process at the organismal level.  
 
It is well known that oxidative stress, inflammation and senescence are intricately 
related (Erusalimsky, 2009, Guzik & Touyz, 2017). Oxidative stress and inflammation 
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are implicated in various age-associated cardiovascular diseases (Guzik & Touyz, 
2017). Our study showed that kallistatin inhibited H2O2-induced endothelial senescence, 
associated with elevated antioxidant gene synthesis, and reduced pro-inflammatory 
gene expression in human endothelial cells. Using pharmacological inhibitors of eNOS 
and SIRT1, this study further revealed that kallistatin through SIRT1 stimulated eNOS 
synthesis. Let-7g has been shown to inhibit endothelial senescence, apoptosis and 
inflammation (Zhang et al., 2013, Liao et al., 2014). We found that kallistatin through Let-
7g upregulation prevented miR-34a-SIRT1-eNOS pathway to achieve its anti-senescent, 
antioxidant and anti-inflammatory actions. Moreover, kallistatin deficiency in mouse lung 
endothelia cells exacerbated senescence, superoxide formation and inflammation in 
conjunction with reduced Let-7g and antioxidant gene expression, and elevated miR-34a 
synthesis. These studies confirmed that endogenous kallistatin is crucial for reducing 
endothelial senescence, oxidative stress and inflammation. These combined findings 
provided new insight into the mechanism of kallistatin in protection against endothelial 
senescence by regulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway.  
 
In this study, we generated two strains of kallistatin knockout mice, endothelial 
cell-specific kallistatin deficient (KSendo-/-) mice and general kallistatin knockout (KS-/-) 
mice, using Loxp-Cre recombination technique. To avoid potential embryonic fatality of 
KS-/- mice, Cre recombinase activity in KS-/- mice were induced by tamoxifen at four to 
five weeks of age. Our previous report showed that kallistatin depletion by neutralized 
antibody injection exacerbates renal and cardiovascular injury in hypertensive rats (Liu 
Y. et al., 2012). Likewise, we observed that systemic depletion of kallistatin in general 
knockout mice worsened aortic oxidative stress and renal fibrosis in STZ-induced 
diabetes. Kallistatin deficiency reduced eNOS and SIRT1 levels and elevated oxidative 
stress in the aorta of diabetic mice. In parallel with the EndMT study, interstitial fibrosis, 
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as indicated by collagen deposition, was further aggravated in kidney of systemic 
kallistatin knockout mice with STZ-induced diabetes. Renal fibrosis was associated with 
reduced capillary density and increased fibroblasts in diabetic KS-/- mice, as evidenced 
by decreased endothelial marker Tie2 and increased mesenchymal marker expression, 
fibronectin and α-SMA. These findings confirmed the protective role of endogenous 
kallistatin in vascular and organ injury. 
 
Besides kallistatin’s beneficial effects on vascular oxidative stress and organ 
fibrosis, our future study will further determine the role of endogenous kallistatin in 
vascular senescence and inflammation using general kallistatin knockout mice with STZ-
induced diabetes. Senescent phenotype and biomarkers in aortas of diabetic KS-/- mice 
will be evaluated. Inflammatory gene expression and histologic investigation for 
inflammatory cell infiltration in vascular or renal section will be examined. We expect that 
the future study could substantiate kallistatin’s crucial role in vascular injury and 





Tissue Homogenization and Plasma Collection 
Tissue Homogenization 
1. Mince mouse tissues on ice into small pieces and homogenize 10 mg of tissue in 500 
µL ice-cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM disodium EDTA, 0.1 mM 
EGTA, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.5% sodium dexoycholate) with 
1% protease inhibitor.  
2. Homogenize thoroughly and keep tissues on ice for 30 min.  
3. Centrifuge the homogenate at high speed (12000 × g) for 30 min at 4°C. 
4. Transfer the supernatant into a new tube and store at -80°C. 
 
Plasma Collection 
1. Collect whole blood into commercially available anticoagulant EDTA-treated capillary 
tubes. 
2. Stand the sample on ice at least 30 min. 
3. Centrifuge at 3000 rpm for 30 min at 4°C. 






RNA Extraction  
1. Add 0.3-0.4 mL of TRIzol Reagent per 1×105-107 cells to lyse the cells. Add 1 mL of 
TRIzol reagent per 100 mg of tissue to homogenize samples. 
2. Incubate for 20 min at room temperature to permit the complete dissociation of 
nucleoprotein complexes. 
3. Add 0.2 mL of chloroform per 1 mL of TRIzol Reagent for phase separation. 
4. Incubate for 2-3 min at room temperature. 
5. Centrifuge the sample for 15 min at 12000 × g at 4°C. 
6. Transfer the aqueous phase to a new tube. Add 0.5 ml of isopropanol to the aqueous 
phase, per 1 mL of TRIzol Reagent used for lysis. 
7. Shake vigorously by hand for 15 s and incubate for 10 min at room temperature. 
8. Centrifuge for 10 min at 12000 × g at 4°C. 
9. Remove the supernatant, wash the RNA pellet once in 1 mL of 75% ethanol per 1 ml 
of TRIzol Reagent used for lysis. 
10. Vortex the sample briefly and centrifuge for 5 min at 7500 × g at 4°C. 
11. Air-dry RNA pellet for 5-10 min. 
12. Dissolve RNA in 20-30 µL DEPC water and incubate in a heat block set at 55-60 °C 
for 10-15 min. 




Appendix 3  
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
For mRNA RT-PCR: 
1. Dilute RNA to 0.2 µg/µL in DEPC H2O. 
2. Prepare the 2 × RT master mix on ice (per 20 µL reaction, Life Technologies) 
Component                                           Volume/ Reaction (µL) 
10×RT buffer                                                                       2.0 
25× dNTP Mix (100 mM)                                                    0.8 
10× RT Random Primers                                                    2.0 
MultiScribe Reverse transcriptase                                      1.0 
RNase Inhibitor                                                                   1.0 
Nuclease-free H2O                                                             3.2 
 Total volume:                                                                     10.0 
 
3. Mix 2 ✕ RT master mix briefly. 
4. Add10 µl of RNA sample to 10 µL of 2 ✕ RT master mix. 
5. Mix well and centrifuge, then load the thermal cycler. 
6. Run PCR cycles (25°C for 10 min, 37°C for 120 min, 85°C for 5 min and 4°C forever). 
 
For miRNA RT-PCR: 
1. Dilute RNA to 0.2 µg/µL in DEPC H2O. 
2. Prepare the RT master mix on ice (per 15 µL reaction, Life Technologies) 
      Component                                                    Volume/ Reaction (µL) 
10 × RT buffer                                                                     1.50 
25 × dNTP Mix (100 mM)                                                     0.15 
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MultiScribe Reverse transcriptase                                      1.00 
RNase Inhibitor                                                                   0.19 
Nuclease-free H2O                                                             4.16 
 Total volume:                                                                     7.00 
 
3. Add 3 µL of 5 × RT primers and 5 µL of RNA sample to each 7 µL master mix.  
4. Mix gently and centrifuge, then load the thermal cycler. 









Appendix 4  
Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) 
For cDNA qPCR amplication 
1. Dilute cDNA to 5-10 ng/µL. 
2. TaqMan® Gene Expression Assay (20 X, primers and probe) is thawed on ice, 
resuspended completely by gently vortexing, then centrifuged briefly. 
3. Mix the master mix reagent by gently swirling the bottle.  
4. Prepare a PCR reaction mix (per 20 µL reaction): 
Component                         Volume per 20 µL Sample    Final Concentration 
TaqMan master mix (2 X)               10.0                           1 X 
Taqman Primer                               1.0                            50 nM 
Water                                               7.0                              _ 
Total Volume                                  18.0                             _ 
5. Mix and transfer 18 µL reaction mix to each well of a 96-well PCR plate. 
6. Add 2.0 µL DNA sample to reaction mix per replicate. 
7. Seal the plate and centrifuge the plate briefly. 
8. Load the plate into the BioRad PCR instrument. 
9. Set thermal cycling conditions: UDG incubation at 50°C for 2 min, AmpliTaq Gold 
enzyme activation at 95°C for 10 min; PCR cycle (X 40): denature at 95°C for 15 s and 
anneal/extend at 60°C for 1 min. 
 
For Small RNA qPCR amplification 
1. Obtain a sterile 1.5 mL microcentrifuge tube for each sample. 
2. Prepare PCR reaction mix (per 20 µL reaction) 
Component                         Volume per 20 µL Reaction (µL) 
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Taqman Small                                    
RNA Assay (20X)                                    1.00 
Product form RT reaction                        1.33 
Taqman Master Mix (2X)                       10.00 
Nuclease-free water                                 7.67 
Total volume                                           20.00 
3. Cap the tube and invert several times to mix. 
4. Centrifuge the tube briefly. 
5. Transfer 20 µL of the complete PCR reaction mix into each well on a 96-well plate. 
6. Seal the plate and centrifuge the plate briefly. 
7. Load the plate into PCR instrument. 





Recombinant Human Kallistatin Purification 
1. Culture 293T HEK His-tag kallistatin cells to 90% confluency at 37°C in 5% CO2 
incubator. 
2. Collect the media and centrifuge at 12000 rpm at 4°C for 30 min. 
3. Suspend supernatant in 80% of ammoniums sulfate. Stir for 2-3 hrs at 4°C. 
4. Centrifuge at 12000 rpm at 4°C for 30 min. 
5. Suspend the pellet in 30 mL of cold ddH2O and then stir at 4°C for 30 min. 
6. Dialyze with 1 mM EDTA 4 × of one litter at 4°C using10000 MW dialysis cassette. 
Centrifuge at 12000 rpm at 4°C for 30 min. 
7. Dialyze with 0.02 M Na2HPO4/0.5 M NaCl, 2 ✕ of one litter. 
8. His-Tag resin (4-5 mL). Mix the protein with His-Tag resin, rotate over night at 4°C. 
9. Next day stop rotating, let it sit for 1 h. Pack the column and wash with 300 mL of 
washing buffer (0.02 M Na2HPO4, 0.5 M NaCl, and 10 mM Imidazole). 
10. Elute with 1 mL of 4 ✕ elution buffer and 5 mL of H2O. 






Prepare the samples: 
1. Homogenize samples in ice-cold lysis buffer (pH 5.0, cacodylic acid 10 mM; NaCl 0.15 
M; ZnCl 20 mM; NaN3 1.5 mM; Triton X-100 0.01% and proteinase inhibitor). 1:3 (wt/vol). 
2. Centrifuge the homogenates for 10 min at 14000 rpm at 4°C. 
3. Measure the protein concentration with pierce BCA assay kit (Thermo scientific). 
 
SDS-PAGE 
1. Prepare the gel: 4% stacking gel and 10% SDS-PAGE polymerized with gelatin type I 
in a final concentration of 1 mg/mL (heat 30 s in microwave). 
2. Load samples: loading buffer (non-reducing: 10% SDS; 4% sucrose; 0.25M Tris HCl 
and 0.1% bromophenol blue pH 6.8). 50 µg sample is diluted at 3:1 with loading buffer, 
without boiling. 
3. Run the gel at 15 mA in stacking gel and 20 mA in separating gel at 4°C. 
 
Gel Washing and Staining: 
1. Incubate gel in renaturing buffer (2.5% Triton-X-100) for 30 min to remove SDS. First 
time 100 mL for 10 min, then change to 100 ml for 20 min. 
2. Wash in 150 mL ddH2O for 10-30 min. 
3. Incubate gel in developing buffer (50 mM Tris pH 8.0; 5 mM CaCl2; 0.2 M NaCl; 0.02% 
Brij-35) for 30 min and change to fresh developing buffer for 16 h at 37°C. 
4. Stain gel with Coomassie blue G-250 solution (dissolve 1.25 g Coomassie Blue G-250 
in 250 mL methanol, then add 250 mL ddH2O and 50 ml acetic acid) for 30 min. 
5. Destain gel with 7% acetic acid, 20% methanol and 73% H2O solution until bands can 




SDS-PAGE and Western Blot Analysis 
SDS-PAGE Solutions 
Separating gel buffer (pH 8.8): 7.38 g Tris-HCl, 30.7 g Tris-Base, 0.8 g SDS in 200 mL 
ddH2O. 
Stacking gel buffer (pH 6.8): 7.9 g Tris-HCl, 0.4 g SDS in 100 mL ddH2O.  
10% ammonium persulfate (AP): 1.0 g AP in 10 mL ddH2O. 
30% acrylamide: 75 g acrylamide, 2 g methylenebisacrylamide in 250 mL ddH2O. 
10 ✕ running buffer (pH 8.3): Tris-Base 30.35 g, glycine 144.0 g, SDS 10.0 g. Bring to 1 
L with ddH2O. 
5 ✕SDS loading buffer (pH 6.8): 1 M Tris-HCl (pH 6.8) 3.75 mL, SDS 1.5 g, DTT 1.16 g, 
bromophenol blue 1.5 mg, glycerol 7.5 mL, ddH2O 7.5 mL. 
 
Prepare SDS-PAGE gel: 
1. Clean the small and large glass plates with ddH2O and 70% ethanol. Set up the glass 
casting apparatus. 
2. Prepare polyacrylamide separating gel solution (for 2 gels, 10 wells): 
Mixture                                                      10% 
ddH2O                                                       4.2 mL 
30% acrylamide                                        3.3mL 
Separating buffer                                      2.5mL 
10% AP                                                     55 µL 




3. Dispense the solution into the casting chamber. Add water slowly until full. Wait 40 
min or until polymerized. 
4. Prepare polyacrylamide stacking solution (for 2 gels, 10 wells): 
ddH2O                                                       1.5 mL 
30% acrylamide                                        375 µL 
Stacking buffer                                          625 µL 
10% AP                                                      7.5 µL 
TEMED                                                        4 µL 
5. Remove the water overlay and dispense the stacking gel solution. Insert the comb.  
Allow 30 min for polymerization. Remove the comb. 
6.Transfer the polymerized gel to the running apparatus. Pour the 1 ✕ running buffer 
until it covers the plates.  
7. Load sample (15-50 µg) after boiling at 100°C for 5 min into the wells.  
8. Run at 180 V for 40-60 min. 
 
Western Blot Solutions 
1 x Transfer buffer (pH 8.3): 3.03 g Tris-Base, 14.4 g glycine, 200 mL methanol, bring to 
1 L with ddH2O. 
10 X Tris-buffered saline (TBS), pH 7.6: 24.2 g Tris-Base, 80 g NaCl dissolved in 1L 
ddH2O. Adjust pH to 7.6 with HCl. 
Tris-buffered saline, 0.1% Tween 20 (TBST): Add 1 mL Tween-20 to 1 L 1 X TBS buffer. 
 
 Gel transfer 
1. Pre-soak sponges, blotting paper and membrane. Add transfer buffer to a plastic tub. 
Place the stack to the black side of the plastic holder in the following order: sponge, 
blotting paper, membrane, gel, blotting pager and sponge. 
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2. Remove all air bubbles and close the plastic holder. Place the transfer sandwich into 
the running chamber. Add ice holder and fill with transfer buffer. 
3. Run at 100 V at 4°C for 1 h. 
 
Detection using chemiluminescence (ECL+Plus) 
1. Rinse the membrane briefly with TBST for 5 min X 2. Block the membrane with 7% 
milk in TBST for 1 hr at room temperature on an orbital shaker. 
2. Wash twice with TBST, 5 min each. 
3. Incubate with primary antibody in 5% milk TBST overnight at 4°C with shaking. 
4. Wash the membrane for 3 X 5 min with TBST. 
4. Incubate with appropriate secondary antibody (1:5000 to 1: 10000 in 5% milk TBST) 
for 1 hr at room temperature. Wash 3 X 10 min with TBST. 
5. Apply chemiluminescence chemicals solution A and solution B at a ratio of 1: 1 (500 
µL each) at dark, for each membrane add enhancer solution A and B (80 µL each). 
6. Drain off excess detection solution and wrap the membrane in Saran Wrap.  
7.	Capture the chemiluminescent signals using a bio-rad camera-based imager. 




NAD(P)H Oxidase Activity Assay 
Solutions: 
Reaction Buffer: 50 mM Na phosphate, pH 7.2, 0.01 mM EDTA, pH 8.0. 
5 mM lucigenin (Sigma M-8010, store at RT) in reaction buffer. 
2 mM NADH (Sigma N8129, stored at 4°C) in reaction buffer. 
2 mM NADPH (Sigma N1630, store at -20°C) in reaction buffer. 
Activity Procedure: 
1. Let the TD-20/20 luminometer warm up for 5 min and set up as follows: 
    a. Inj 1: OFF, Inj 2: OFF 
    b. Set up: Delay = 5 sec, Integrate = 900 sec, Replicate = 1 
    c. Set up: 888, set sensitivity to 60.1 % 
2. Once set up is complete, prepare NADPH blanks in cuvettes and record light intensity. 
              reaction buffer                    1.37 mL 
             5 mM lucigenin                    75 µL (250 µM) 
             2 mM NADH or NADPH      55 µL (100 µM) 
                                                         1.5 mL 
3. Prepare sample reaction mixtures in cuvettes and record light intensity. 
             reaction buffer                     1.35 mL 
             5 mM lucigenin                     75 µL (250 µM) 
             2 mM NADH or NADPH       55 µL (100 µM) 
              sample                                20 µL    
                                                         1.5 mL 
4. Calculate activity as follows: 
        (sample intensity - blank intensity)         = rlu/mg protein/min 




Transfection of MicroRNA-34a Mimic or Let-7g Inhibitor 
1. One day before transfection, culture cells (in 12-well plate) in 500 µL of growth 
medium without antibiotics such that they will be 30-50% confluent at the time of 
transfection.  
2.  For each well to be transfected, prepare RNAi duplex-Lipofectamine® RNAiMAX 
complexes as follows: 
A. Dilute 6 pmol miRN-34a mimic or control siRNA in 50 µL Opti-MEM® I Reduced 
Serum Medium without serum. Mix gently. 
B. Mix Lipofectamine™ RNAiMAX gently before use, then dilute 1 µL in 50 µL Opti-
MEM® I Reduced Serum Medium. Mix gently. 
C. Combine the diluted RNAi duplex with the diluted Lipofectamine™ RNAiMAX. Mix 
gently and incubate for 10-20 min at room temperature. 
3.  Add the RNAi duplex-Lipofectamine® RNAiMAX complexes to each well containing 
cells. This gives a final volume of 600 µL and a final RNA concentration of 10 nM. Mix 
gently by rocking the plate back and forth. 
4. Incubate the cells 6-12 h at 37°C in a CO2 incubator until you are ready to assay for 
gene knockdown. Medium may be changed after 4-6 h. 





Appendix 10  
Telomerase Activity 
Extract Preparation 
1. Pellet the cells or tissue, wash once with PBS, repellet, and carefully remove all PBS.  
2. Resuspend the cell pellet in 200 µL of CHAPS lysis buffer/105-106 cells.  
3. Incubate the suspension on ice for 30 min. 
4. Spin the sample in a microcentrifuge at 12,000 x g for 20 min at 4°C. 
5. Transfer 160 µL of the supernatant into a fresh tube and determine the protein 
concentration. For cell extract concentration should be 10-750 ng/µL.  
6. Aliquot and quick-freeze the remaining extract on dry ice, and store at -80°C. 
Required Controls and Samples: 
5X TRAPEZE® RT Reaction Mix*                  5.0 µL 
Taq Polymerase (5 units/µL)                          0.4 µL (2 Units) 
Nuclease Free Water                                     17.6 µL 
Samples:                                                         2.0 µL 
(TSR8 dilutions, positive extract control, telomerase negative, NTC, experimental 
samples +/- heat treatment) 
                                      TOTAL VOLUME 25.0 µL 
PCR Amplification 
1. Set-up the real-time experiment to include the following PCR parameters. 
30°C 30 min 1 cycle 
95°C 2.0 min 1 cycle 
94°C 15  
59 °C 60 sec                      ✕ 45 
*45°C 10 sec 




Genotyping and DNA Electrophoresis 
DNA Extraction from Tail Biopsy  
1) Cut 0.5 cm tail from each mouse at 3 week-old age. 
2) Transfer tail biopsy to 150 µL lysis solution 1 (500 mL: 1.25 mL 10 M NaOH; 2 mL 0.5 
M EDTA; 496.75 mL ddH2O). Incubate samples in 90°C heater block for 45 min. 
3) Centrifuge briefly and add 150 µL Solution 2 (pH 7.4, 40 mM Tris). Vortex briefly. 
 
Genotyping: 
1. Primers: Serpina3c-A1Loxp-F, Serpina3c-A1Loxp-R; Seripina3c-Frt-F, Seripina3c-Frt-
R; Cre-F, Cre-R; LRL-040-A1 Loxp-F, LRL-040-A1 Loxp-R. 
2. Prepare a PCR reaction mix in a PCR tube (per 25 µL reaction): 
Component                      Volume per 25 µL Sample (µL)    
AmpliTaq Gold 
360 master mix                             12.5                            
Forward Primer                             1.0          
Reverse Primer                             1.0                             
DNA                                               2.0 
Water                                             8.5                               
Total Volume                                 25.0                              
3. PCR cycling parameters as below: 
      95 °C 2 min 
      95 °C 30 sec 
      63 °C 30 sec     X 35 
      72 °C 25 sec 
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      72 °C 10 min 
       4°C Finished 
 
DNA Electrophoresis 
1. Prepare 3% agarose gel (3 g in 100 mL 1 X Tris-acetate-EDTA buffer, heated in 
microwave for 1-2 min). 
2. Cool down the agarose solution to around 60 °C, add a final concentration of 5 µg/mL 
ethidium bromide and mix well. 
3. Place comb into casting tray and pour the solution to casting tray. 
4. Let casting tray sit for 5 min at 4°C or 30 min at room temperature. 
5. Add 2 µL 10 X DNA loading buffer to each sample. 
6. Set up gel electrophoresis unit. Fill gel box with 1 X TAE until complete covered. 
7. Load molecular weight marker and samples into gel wells. 
8. Run gel at 130 V for 40 min. 





Isolation of Mouse Lung Endothelial Cells 
Digestion Lung Samples 
1. Remove whole lungs of the mouse. Wash whole lungs with serum-free basal-DMEM. 
Chop the lung tissue using sterile, disposable blades to very small pieces. 
2. Transfer the pieces into a 15-mL centrifuge tube containing 1 X working dilution of 
collagenase digestive solution (7–10 mL per 0.5 g of wet tissue).  
3. Digest the lung at 37°C for 45 min under continuous horizontal shaking (300 r.p.m.). 
Quench the lung-digestive solution mixture with an equal volume of complete-DMEM. 
4. Strain the lung digest through the 70-mm cell strainers by releasing the lung digest on 
the cell strainer using a 5-mL pipette. 
5. Restrain cell suspension through a 40-µm cell strainer into a 50-mL centrifuge tube. 
6. Centrifuge the 50-mL tube at 300 X g at 4°C for 10 min. 
7. Decant the supernatant and resuspend the cell pellet in 10 mL of complete-DMEM. 
8. Centrifuge the 50-mL tube at 300 X g at 4°C for 10 min. 
9. Decant the supernatant and resuspend the cell pellet in 5 mL of MACS buffer (0.5 % 
BSA, 2 mM EDTA in PBS). Determine cell number. 
 
Magnetic Labeling 
10. Add 90 µL of buffer per 107 total cells to the cell pellet. Add 10 µL of CD31 
microbeads per 10⁴ total cells. Mix well and incubate for 15 min in the refrigerator. 
11. Wash cells by adding 1−2 mL of buffer per 10⁴ cells and centrifuge at 300 X g for 10 
min. Aspirate supernatant completely. 





13. Prepare column by rinsing with 3 mL MACS buffer for each LS column. 
14. Apply cell suspension onto the column. Collect flow-through containing unlabeled 
cells. 
15. Wash column with 3 ✕ 3 mL MACS buffer. Collect unlabeled cells that pass through 
and combine with the flow-through from step 3. 
16. Remove column from the separator and place it on a suitable collection tube. 
17. Pipette 5 mL MACS buffer onto the column. Immediately flush out the magnetically 
labeled cells by firmly pushing the plunger into the column. 
18. Centrifuge for 5 min. Resuspend cells with EBM-2 media and culture cells in gelatin-
coated dishes. 





Appendix 13  
Immunocytochemistry 
1. Aspirate the culture media of cells grown in 6- or 12-well plates, then cover cells with 
4% formaldehyde diluted in 1 × PBS. 
2. Allow cells to fix for 15 min at room temperature. 
3. Aspirate fixative, rinse 3 times in 1 × PBS for 5 min each. 
4. Block specimen in blocking buffer (1 × PBS / 3% BSA / 0.2% Triton X-100) for 60 min. 
5. Aspirate blocking buffer, apply diluted primary antibody in antibody dilution buffer (1 
×PBS / 1% BSA / 0.3% Triton X-100) and incubate overnight at 4°C. 
6. Rinse 3 times in 1 × PBS for 5 min each. 
7. Incubate specimen in fluorochrome-conjugated secondary antibody diluted in antibody 
dilution buffer for 1-2 h at room temperature in the dark. 
8. Rinse 3 times in 1 × PBS for 5 min each. 
9. Counterstain the nuclei with Hoechst 33343 (5 µg/mL in PBS) for 5 min. 






Picosirius Red Staining 
Solutions: 
0.2% Phosphomolybdic Acid (PMA): 0.2 g PMA in 100 mL ddH2O. 
1% aqueous solution Sirius red: 0.5 g in 50 mL ddH2O. 
Sirius red in picric acid: 10 mL of 1% aqueous solution, 90 mL saturated picric acid, pH 
2.0. Let the solution sit for 24 h at room temperature. 
 
Procedure 
1. Deparaffinize and rehydrate paraffin-embedded sections to water. 
2. Incubate slides in 0.2% PMA for 5 min. 
3. Rinse briefly in distilled water. 
4. Stain in picosirius red solution (pH 2.0) for 90 min. 
5. Rinse in 0.01 N HCl, change solution in jars for 3 or 4 times. 








Staining solution: 40 mM citric acid/sodium phosphate (pH 6.0), 0.15 M NaCl, 2 mM 
MgCl2. 
100 ✕ Staining solution supplement A: 500 mM potassium ferrocyanide. 
100 ✕ Staining solution supplement B: 500 mM potassium ferricyanide. 
Fixative solution: 2% formaldehyde, 0.2% glutaraldehyde in 1 ✕ PBS 
β-gal staining solution: For each 35 mm well to be stained, add 930 µL staining solution, 
10 µL staining supplement A, 10 µL staining supplement B, 50 µL 20 mg/mL X-gal in 
DMF into a polypropylene container. Adjust pH to 5.9-6.1. 
 
Procedure 
1. Rinse the cell culture plate one time with 1 ✕ PBS (2 mL for a 35 mm well). 
2. Add 1 mL of fixative solution to each 35 mm well. Allow cells to fix for 10-15 min at 
room temperature. 
3. Rinse the plate two times with 1 ✕ PBS. 
4. Add 1 mL of the β-gal staining solution to each 35 mm well. Incubate the plate at 37°C 
overnight in a dry incubator (no CO2). 
5. Check the cells under a microscope (200 ✕ magnification) for the development of blue 
color. 
6. For long-term shortage of the plates, remove the β-gal staining solution and overlay 
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